0001493152-18-015639.txt : 20181113 0001493152-18-015639.hdr.sgml : 20181113 20181113063120 ACCESSION NUMBER: 0001493152-18-015639 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDONOVO THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001528172 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452552528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55453 FILM NUMBER: 181174884 BUSINESS ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 BUSINESS PHONE: (800) 489-4774 MAIL ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfolio Acquisitions, Inc. DATE OF NAME CHANGE: 20110920 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfoliio Acquisitions, Inc. DATE OF NAME CHANGE: 20110817 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended September 30, 2018.

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _______ to _______.

Commission File Number: 000-55453

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	45-2552528
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367

(Address of principal executive offices, zip code)

(800) 489-4774

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ X ] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ X ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [ ] (do not check if smaller reporting company)	Smaller reporting company [X]
	Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of November 13, 2018, there were 395,129,771 shares of common stock, $0.0001 par value issued and outstanding.

ENDONOVO THERAPEUTICS, INC.

TABLE OF CONTENTS

FORM 10-Q REPORT

September 30, 2018

		Page Number
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements.	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	26
Item 4.	Controls and Procedures.	26

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.	27
Item 1A.	Risk Factors.	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	28
Item 3.	Defaults Upon Senior Securities.	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information.	28
Item 6.	Exhibits.	29

SIGNATURES		30

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	September 30,			December 31,
	2018			2017
	(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	665,244		$	90,173
Accounts receivable		2,650			-
Prepaid expenses and other current assets		21,000			21,000
Total current assets		688,894			111,173

Property Plant and Equipment, net		7,741			1,064
Patents, net		4,014,817			4,500,000
Total assets	$	4,711,452		$	4,612,237

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	3,179,602		$	2,714,041
Short term advances		-			20,323
Notes payable, net of discounts of $1,175,627 as of Septebmer 30, 2018 and $2,624,984 as of December 31, 2017		6,966,896			4,461,160
Notes payable - related parties		270,000			270,000
Derivative liability		7,057,172			5,939,600
Current portion of long term loan		-			4,221
Total current liabilities		17,473,670			13,409,345

Series C preferred stock liability, net of discounts of $152,972 at September 30, 2018 and $101,808 as of December 31, 2017		1,164,528			598,192
Acquisition payable		155,000			155,000
Total liabilities		18,793,198			14,162,537
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders’ deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at September 30, 2018 and December 31, 2017		5			5
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at September 30, 2018 and December 31, 2017		1			-
Common stock, $0.0001 par value;
2,500,000,000 shares authorized; 381,375,857 and 316,951,712 shares issued and outstanding as of Septermber 30, 2018 and December 31, 2017		38,136			31,692
Additional paid-in capital		22,884,078			19,604,016
Stock subscriptions		(1,570	)		(1,570	)
Accumulated deficit		(37,002,396	)		(29,184,443	)
Total shareholders’ deficit		(14,081,746	)		(9,550,300	)
Total liabilities and shareholders’ deficit	$	4,711,452		$	4,612,237

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017

Revenue	$	21,306		$	-		$	41,132		$	-
Cost of revenue		4,312			-			4,862			-
Gross profit		16,994			-			36,270			-

Operating expenses		1,052,210			1,035,628			3,163,485			3,770,929
Loss from operations		(1,035,216	)		(1,035,628	)		(3,127,215	)		(3,770,929	)

Other income (expense)
Change in fair value of derivative liability		(3,431,939	)		(4,544,656	)		(970,760	)		(6,945,434	)
Gain (loss) on settlement of debt		49,806			(58,197	)		308,151			2,175,459
Settlement expenses		-			(80,000	)		-			(80,000	)
Interest expense, net		(1,530,847	)		(953,623	)		(4,028,129	)		(3,958,187	)
Other income (expense)		(4,912,980	)		(5,636,476	)		(4,690,738	)		(8,808,162	)

Loss before income taxes		(5,948,196	)		(6,672,104	)		(7,817,953	)		(12,579,091	)

Provision for income taxes		-			-			-			-

Net loss	$	(5,948,196	)	$	(6,672,104	)	$	(7,817,953	)	$	(12,579,091	)

Basic and diluted loss per share	$	(0.02	)	$	(0.03	)	$	(0.02	)	$	(0.06	)
Weighted average common shares outstanding:
Basic and diluted		369,234,308			263,535,090			348,379,894			220,353,026

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months ended September 30,
	2018			2017
Operating activities:
Net loss	$	(7,817,953	)	$	(12,579,091	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense		487,474			11,070
Fair value of shares issued for services		130,235			1,410,071
Gain on extinguishment of debt		(308,151	)		(2,175,459	)
Amortization of note discount and original issue discount		2,647,939			1,467,888
Amortization of discount on Series C Preferred stock liability		61,912			-
Non-cash interest expense		623,917			2,465,912
Non-cash value of warrant and stock options issued for services		382,473			-
Change in fair value of derivative liability		970,760			6,945,434
Changes in assets and liabilities:
Accounts receivable		(2,650	)		-
Prepaid expenses and other current assets		-			156,321
Accounts payable and accrued expenses		661,305			108,658
Net cash used in operating activities		(2,162,739	)		(2,189,196	)

Investing activities:
Acquisition of property and equipment		(8,969	)		-
Net cash used in investing activities		(8,969	)		-

Financing activities:
Proceeds from the issuance of notes payable		2,336,000			1,562,000
Proceeds from related party short-term advances		65,000			12,650
Repayments on related parties short term advances		(87,000	)		(11,500	)
Proceeds from issuance of preferred stock		135,000			5
Proceeds from issuance of common stock and units		60,000			740,250
Payment against long term loan		(4,221	)		(9,263	)
Payment against notes payable		(375,500	)		(96,000	)
Proceeds from issuance of redeemable shares		617,500			-
Net cash provided by financing activities		2,746,779			2,198,142

Net increase in cash		575,071			8,946
Cash, beginning of year		90,173			55,533
Cash, end of period	$	665,244		$	64,479

Supplemental disclosure of cash flow information:
Cash paid for interest	$	122,445		$	27,022
Cash paid for Preferred C dividends	$	37,950		$	-
Cash paid for income taxes	$	-		$	-

Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$	1,237,256		$	1,108,321
Reduction in note payable and accrued interest as result of settlement	$	82,000		$	-
Common stock issued on settlement of debt	$	-		$	289,675
Notes payable and accrued interest exchanged for common stock units	$	-		$	66,367
Value of stock options granted in satisfaction of deferred compensation	$	-		$	1,467,311

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Deficit

(Unaudited)

	Series AA Preferred Stock				Series B Convertible Preferred Stock				Common Stock				Additional Paid-in		Common Stock Subscription			Retained			Total Shareholder’s
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Receivable			Earnings			Deficit

Balance December 31, 2017		5,000	$	5		-	$	-		316,951,712	$	31,692	$	19,604,016	$	(1,570	)	$	(29,184,443	)	$	(9,550,300	)

Private placement units issued for cash		-		-		-		-		1,561,950		156		59,844		-			-			60,000
Preferred stock issued for cash		-		-		1,350		1		-		-		134,999		-			-			135,000
Shares issued for services		-		-		-		-		4,150,000		416		129,819		-			-			130,235
Shares issued with lock-up agreements		-		-		-		-		17,003		2		1,044		-			-			1,046
Shares issued for conversion of notes payable and accrued interest		-		-		-		-		58,695,192		5,870		2,367,869		-			-			2,373,739
Valuation of warrants issued with Preferred Series C		-		-		-		-		-		-		113,076		-			-			113,076
Valuation of warrant and stock options issued for services		-		-		-		-		-		-		382,473		-			-			382,473
Valuation of warrant issued with note payable		-		-		-		-		-		-		71,521		-			-			71,521
Valuation of warrants issued for extension of notes		-		-		-		-		-		-		19,417		-			-			19,417
Net loss for the period ended September 30, 2018		-		-		-		-		-		-		-		-			(7,817,953	)		(7,817,953	)
Balance September 30, 2018		5,000	$	5		1,350	$	1		381,375,857	$	38,136	$	22,884,078	$	(1,570	)	$	(37,002,396	)	$	(14,081,746	)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

Note 1 - Organization and Nature of Business

Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electroceutical™ device.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.

Going Concern

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

Net Income (Loss) per Share

Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

Accounts Receivable

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.

Research and Development

Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements.

In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements.

In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2.

In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements.

In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

2. Revenue Recognition

Contracts with Customers

We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.

We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

During the three months ended September 30, 2018, we recognized gross revenue of $21,306 from products we sold as a principal in the transaction. During the nine months ended September 30, 2018, we recognized net revenue of $17,045 from products with a selling price of $43,196 and gross revenue of $24,087 from products we sold as a principal in the transaction.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

Plastic Surgeons

As of September 30, 2018 and 2017 the sources of revenue were as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017

Distributor- Plastic surgeons, net	$	-	$	-	$	17,045	$	-
Direct sales- Plastic surgeons, gross		21,306		-		24,087		-
Total sources of revenue	$	21,306	$	-	$	41,132	$	-

Warranty

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

Significant Judgments in the Application of the Guidance in ASC 606

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Practical Expedients

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Taxes Collected from Customers

Taxes collected on the value of transaction revenue are excluded from product revenues and are accrued in current liabilities until remitted to governmental authorities.

Effective Date and Transition Disclosures

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

Note 3 – Property, Plant and Equipment

The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017:

	September 30,		December 31,
	2018		2017

Autos	$	64,458	$	64,458
Medical equipment		13,969		5,000
Other equipment		8,774		8,774
		87,201		78,232
Less accumulated depreciation		79,460		77,168
	$	7,741	$	1,064

Depreciation expense for the nine months ended September 30, 2018 and 2017 was $2,292 and $11,070, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.

Note 4 – Patents

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017:

	September 30,		December 31,
	2018		2017

Patents	$	4,500,000	$	4,500,000

Less accumulated amortization		485,183		-

	$	4,014,817	$	4,500,000

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

Amortization expense associated with patents was $485,183 and $0 for the nine months ended September 30, 2018 and 2017. The estimated future amortization expense related to patents as of September 30, 2018 is as follows:

Twelve Months Ending September 30,	Amount

2019	$	646,910
2020		646,910
2021		646,910
2022		646,910
2023		646,910
Thereafter		780,267
Total	$	4,014,817

Note 5 - Notes Payable and Long Term Loan

Notes Payable

During the nine months ended September 30, 2018, the Company issued Convertible Notes (“Variable Notes”) totaling $923,870 for funding of $836,000 with original terms of one year and an interest rate of 10%, and a variable conversion rate with discounts of 35% of the Company’s common stock based on the terms included in the Variable Note. The Variable Notes contains a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premiums of 135%. The Company also issued Fixed Rate Notes (“Fixed Rate Notes”) totaling $1,683,000 for funding of $1,500,000 with original terms of six months and an interest rate ranging from 10% to 12%.

The gross amount of all convertible notes with variable conversion rates outstanding at September 30, 2018 is $4,212,620, of which $1,488,750 is past maturity.

Notes payable to a related party in the aggregate amount of $270,000 were outstanding at September 30, 2018, of which $100,000 is past maturity.

As of September 30, 2018, other notes payable outstanding totaled $3,929,903, of which $1,329,903 is past maturity.

	September 30,			December 31,
	2018			2017

Notes payable at beginning of period	$	7,356,144		$	3,193,956
Notes payable issued		2,606,870			5,837,070
Settlements on note payable		(47,500	)		(95,597	)
Repayments of notes payable in cash		(375,500	)		(96,000	)
Less amounts converted to stock		(1,127,491	)		(1,483,285	)
Notes payable at end of period		8,412,523			7,356,144
Less debt discount		(1,175,627	)		(2,624,984	)
	$	7,236,896		$	4,731,160

Notes payable issued to related parties	$	270,000		$	270,000
Notes payable issued to non-related parties	$	6,966,896		$	4,461,160

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

The maturity dates on the notes payable are as follows:

Twelve months ending,	Non-related parties		Related parties		Total
Past due	$	2,818,653	$	100,000	$	2,918,653
September 30, 2019		5,323,870		170,000		5,493,870
Total	$	8,142,523	$	270,000	$	8,412,523

Note 6 - Shareholders’ Deficit

Increase in Authorized Shares

On September 18, 2018, an increase in authorized capital stock from 505,000,000 to 2,505,000,000 became effective, of which 5,000,000 shares shall be Preferred Stock, and 2,500,000,000 shall be Common Stock.

Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

	Number of Shares		Number of Shares Outstanding		Par		Liquidation
	Authorized		at September 30, 2018		Value		Value
Series AA		1,000,000		5,000	$	0.0001	$	-
Preferred Series B		50,000		1,350	$	0.0001	$	100
Preferred Series C		8,000		1,318	$	0.0001	$	1,000
Undesignated		3,942,000		-		-		-

Series AA Preferred Shares

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stock holders will receive no dividends nor any value on liquidation. As of September 30, 2018, there were 5,000 shares of Series AA Preferred stock outstanding.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

Series B Convertible Preferred Stock

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of September 30, 2018, 1,350 shares of Series B and 4,805,600 warrant shares have been issued and are outstanding.

Series C Secured Redeemable Preferred Stock

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheets as of September 30, 2018 and December 31, 2017. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. As of September 30, 2018, the Company has sold 1,318 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 5,996,546 shares of common stock for consideration of $1,317,500. The warrants resulted in a debt discount of $152,972 and $101,808 at September 30, 2018 and December 31, 2017, respectively, and are recorded as a discount to the preferred stock liability on the consolidated balance sheet.

Common Stock

During the nine months ended September 30, 2018, the Company issued pursuant to a private placement offering 1,561,950 shares of common stock and the same number of warrants for cash of $60,000. The Company also issued 58,695,192 shares of common stock for the conversion of notes and accrued interest in the amount of $1,237,256.

During the nine months ended September 30, 2018, the Company issued 17,003 shares of common stock valued at $1,046 related to the extension of outstanding notes and lock-up agreements.

During the nine months ended September 30, 2018, the Company issued 4,150,000 shares of common stock with a value of $130,235, related to services and fees.

During the nine months ended September 30, 2018, the Company issued 3,387,534 shares of common stock with a value of $116,531 as a commitment to repay a note payable on its stated terms. Since the note was satisfactorily repaid, the shares and commitment fee were rescinded.

The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

Stock Options

The balance of all stock options outstanding as of September 30, 2018 is as follows:

			Weighted		Weighted Average
			Average Exercise Price		Remaining Contractual		Aggregate Intrinsic
	Options		Per Share		Term (years)		Value
Outstanding at January 1, 2018		93,203,369	$	0.029		3.96
Granted		1,000,000	$	0.030		1.86
Cancelled		-	$	-		-
Exercised		-	$	-		-
Outstanding at September 30, 2018		94,203,369	$	0.029		3.19	$	2,232,620

Exercisable at September 30, 2018		93,286,702	$	0.029		3.21	$	2,210,895

Warrants

During the nine months ended September 30, 2018, in conjunction with the sale of Common Stock, the Company issued three-year common stock purchase warrants to acquire up to 1,561,950 shares of common stock with exercise prices ranging from $0.0734 to $1.00 per share.

In addition, during the nine months ended September 30, 2018, the Company issued a five-year common stock purchase warrant to acquire up to 2,000,000 shares of common stock valued at $71,521 with an exercise price of $0.05 in conjunction with the issuance of a note payable; three-year common stock purchase warrants to acquire up to 4,805,600 shares of common stock with exercise prices ranging from $0.051 to $1.00 in conjunction with the issuance of Series B preferred stock; two-year common stock purchase warrants to acquire up to 3,271,277 shares of common stock with exercise prices ranging from $0.0250 to $0.0516 in conjunction with the issuance of Series C preferred stock; a 2-year common stock purchase warrant to acquire up to 6,200,000 shares of common stock valued at $380,750 with an exercise price of $0.0001; and two-year common stock purchase warrants to acquire up to 642,157 shares of common stock with exercise prices ranging from $0.0368 to $0.0370 in conjunction with the extension of certain notes payable.

The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions:

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

	Nine months ended September 30,
	2018

Expected term		2 years - 5 years
Exercise price		$0.0001-$0.0516
Expected volatility		158%-193%
Expected dividends		None
Risk-free interest rate		1.92% to 2.81%
Forfeitures		None

A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below:

	Outstanding Warrants
				Weighted Average
				Exercise Price
	Shares			Per Share
Outstanding at January 1, 2018		61,807,992		$	0.31
Granted		18,480,984		$	0.20
Cancelled		(300,000	)	$	0.81
Exercised		-		$	-
Outstanding at September 30, 2018		79,988,976		$	0.28

Exercisable at September 30, 2018		79,988,976		$	0.28

Note 7 – Related Party Transactions

One executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from related parties at September 30, 2018 is $270,000.

As of September 30, 2018 and December 31, 2017, the balance of executives’ deferred compensation is $942,650 and $922,425, respectively.

From time-to-time executives of the Company advance monies to the Company to cover costs. During the nine months ended September 30, 2018, executives advanced $65,000 of funds to the Company and received payments of $87,000 resulting in a $0 balance of short-term advances due to executives at September 30, 2018.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

Note 8 – Fair Value Measurements

The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

	Nine months ended September 30,
	2018		2017

Expected term		1 month - 1 year		1 month - 1 year
Exercise price		$0.0129-$0.0326		$0.0085-$0.0385
Expected volatility		119%-195%		189%-201%
Expected dividends		None		None
Risk-free interest rate		1.79% to 2.59%		1.03% to 1.31%
Forfeitures		None		None

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018:

	Derivative
	Liability
Balance December 31, 2017	$	5,939,600

Issuance of convertible debt		1,459,645
Settlements by debt settlement		(1,312,833	)
Change in estimated fair value		970,760

Balance September 30, 2018	$	7,057,172

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018:

Endonovo Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (continued)

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total

As of September 30, 2018
Derivative liability	$	-	$	-	$	7,057,172	$	7,057,172
Total	$	-	$	-	$	7,057,172	$	7,057,172

Note 9 – Commitments and Contingencies

Legal Matters

The Company may become involved in various legal proceedings in the normal course of business.

Note 10 – Subsequent Events

Subsequent to September 30, 2018, an aggregate of 9,236,938 shares of restricted common stock were issued on the conversion of $188,750 of principal and $23,106 of accrued interest pursuant to three Variable Notes.

Subsequent to September 30, 2018, 575,800 shares of restricted common stock were issued on the conversion of $15,000 of principal and $5,153 of accrued interest pursuant to one Fixed Rate Note and issued 3-year warrants for an exercise of up to 575,800 shares of common stock with exercise prices ranging from $0.069 to $1.00.

Subsequent to September 30, 2018, the Company received $85,000 of cash from the issuance of 85 shares of Preferred C Stock and issued two-year warrants for the exercise up to 381,803 shares of common stock with an exercise prices ranging from $0.0380 to $0.0470.

Subsequent to September 30, 2018, 1,000,000 shares of restricted common stock were issued related to services rendered.

Subsequent to September 30, 2018, 2,941,176 shares of restricted common stock were issued on the conversion of 750 shares of Preferred B Stock at a conversion rate of $0.0255 per common share.

As a result of these issuances, the total number of common shares outstanding is 395,129,771. Preferred B shares outstanding is 600 and Preferred C shares outstanding is 1,403.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward Looking Statements

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

This filing contains a number of forward-looking statements which reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” and variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Overview

Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ENDV” “we” “us” “our”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electrocuetical™ device and intellectual property licensing and commercialization.

Our intellectual property management and commercialization segment is focused primarily on licensing various commercially desirable technologies and patents from companies that need operating capital or that need help commercializing their technology and sublicense such technology in designated territories. This segment acquires exclusive licenses for marketable technology normally without the payment of any upfront license fee to the licensor and thereafter, to sub-license the technology in the designated markets, including Asia, Europe, and Brazil. Our results depend upon our ability to locate available, licensable, and readily marketable technology, to negotiate favorable licenses for such technology, and to sub-license the technology in the designated markets at a sufficient level of volume in an effort to generate maximum revenues. Due to the history of our acquisitions, as set forth below, and management’s assessment of what has been the most promising of our technologies, we have determined to focus ourselves as a developer of non-invasive medical devices, more particularly medical devices configured to deliver our Electroceutical™ Therapies. We are commercial stage developer of non-invasive medical devices designed to deliver our proprietary Electroceutical™ Therapies for the treatment of inflammatory conditions, cardiovascular diseases, chronic kidney disease and central nervous system disorders.

First Commercial Sales of SofPulse®

On January 22, 2018, the Company announced the first commercial sales of its FDA-Cleared Electroceutical™ System, SofPulse®, for the palliative treatment of post-operative pain and edema in superficial soft tissues. SofPulse® is being prescribed by physicians for use in post-surgical pain relief and recovery. The Company is working to continue expanding the number of physicians and cosmetic surgeons prescribing SofPulse® for post-operative pain relief and recovery.

Our commercialization efforts have been partially delayed due to manufacturing shortages of the Ivivi Roma Electroceutical™ System we plan to sell and rent to acute care and skilled nursing facilities. The Ivivi Roma Electroceutical™ System has not been manufactured in approximately 6 years and we are currently sourcing various components to build sufficient units to fulfill several pending orders from skilled nursing facilities. However, we will be required to redesign the Ivivi Roma Electroceutical™ System with newer readily available components to ensure a sufficient supply of inventory to fulfill contemplated and pending orders and continue our commercialization efforts.

Going Concern

Our independent registered auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended December 31, 2017 that states that our ongoing losses and lack of resources causes doubt about our ability to continue as a going concern.

Critical Accounting Policies

A summary of our significant accounting policies is included in Note 1 of the “Notes to Consolidated Financial Statements,” contained in our Form 10-K for the year ended December 31, 2017. Management believes that the consistent application of these policies enables us to provide users of the financial statements with useful and reliable information about our operating results and financial condition. The summary consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., which require us to make estimates and assumptions. Other than the new revenue recognition standard that became effective at the beginning of 2018, we did not experience any significant changes during the nine months ended September 30, 2018 in any of our Critical Accounting Policies from those contained in our Form 10-K for the year ended December 31, 2017.

New Accounting Pronouncements

See Note 1 of Notes to Condensed Consolidated Financial Statements for further discussion of new accounting standards that have been adopted or are being evaluated for future adoption.

Results of Operations

Three Months ended September 30, 2018 and 2017

	Three Months Ended September 30,						Favorable
	2018			2017			(Unfavorable)			%

Revenue	$	21,306		$	-		$	21,306			NM
Cost of revenue		4,312			-			(4,312	)		NM
Gross profit		16,994			-			16,994			NM

Operating expenses		1,052,210			1,035,628			(16,582	)		-1.6	%

Loss from operations		(1,035,216	)		(1,035,628	)		412			0.0	%

Other income (expense)		(4,912,980	)		(5,636,476	)		723,496			12.8	%

Net loss	$	(5,948,196	)	$	(6,672,104	)	$	723,908			10.8	%

Revenue

Revenue of the Company’s SofPulse® product during the current quarter in an amount of $21,306 compared to no sales during the previous year corresponding period.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

It is anticipated that sales will increase in future quarters.

Cost of Revenue

Cost of revenue was $4,312 during the three months ended September 30, 2018 compared to no cost of revenue during the previous year corresponding period. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue.

It is anticipated that cost of revenue will increase in future quarters.

Operating Expenses

Operating expenses were stable at $1,052,210 for the three months ended September 30, 2018 compared to $1,035,628 for the corresponding period of the previous year. There was a reduction in consulting and professional expenses of approximately $98,000 related primarily to stock based compensation recorded in 2017, a reduction of research and development costs of approximately $70,000, offset by an increase in amortization of patent costs of approximately $162,000 as the result of acquiring the patent portfolio of RGN in late 2017 and approximately $23,000 of other expenses.

Other Income (Expense)

Other income (expense) for the quarter ended September 30, 2018 was expense of $4,912,980 compared to expense of $5,636,476 for the quarter ended September 30, 2017. This change was due primarily to a change in valuation of our derivative liabilities and net of interest expense resulting from the amortization of the discounts on notes payable. In addition, we had a gain on settlement of debt of $49,806 during the quarter ended September 30, 2018 compared to a loss of $58,197 during the quarter ended September 30, 2017. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of these derivative liabilities.

Nine months ended September 30, 2018 and 2017

	Nine Months Ended September 30,						Favorable
	2018			2017			(Unfavorable)			%

Revenue	$	41,132		$	-		$	41,132			NM
Cost of revenue		4,862			-			(4,862	)		NM
Gross profit		36,270			-			36,270			NM

Operating expenses		3,163,485			3,770,929			607,444			16.1	%

Loss from operations		(3,127,215	)		(3,770,929	)		643,714			17.1	%

Other income (expense)		(4,690,738	)		(8,808,162	)		4,117,424			46.7	%

Net loss	$	(7,817,953	)	$	(12,579,091	)	$	4,761,138			37.8	%

Revenue

The Company initiated sales of its SofPulse® product during the nine months ended September 30, 2018 in an amount of $41,132 compared to no sales during the previous year corresponding period.

It is anticipated that sales will increase in future quarters.

Cost of Revenue

Cost of revenue was $4,862 during the nine months ended September 30, 2018 compared to no cost of revenue during the previous year corresponding period. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue.

It is anticipated that cost of revenue will increase in future quarters.

Operating Expenses

Operating expenses decreased $607,444, a decrease of 16.1%, to $3,163,485 for the nine months ended September 30, 2018 compared to $3,770,929 for the corresponding period of the previous year. The primary reasons for this decrease were the reduction in consulting and professional expenses of approximately $100,000 related primarily to legal fees and deferred compensation expense, the reduction in stock based compensation in an amount of approximately $1,139,000 related to stock options issued to independent contractors in 2017, partially offset by an increase in amortization of patent costs of approximately $485,000 as the result of acquiring the patent portfolio of RGN in late 2017 and an increase in research and development of approximately $48,000.

Other Income (Expense)

Other income (expense) for the nine months ended September 30, 2018 was expense of $4,690,738 compared to expense of $8,808,162 for the nine months ended September 30, 2017. This change was due primarily to a reduction in valuation of our derivative liabilities of approximately $5,974,000 offset by a decrease on gain on settlement of debt of approximately $1,867,000. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of these derivative liabilities.

Liquidity and Capital Resources

	As of						Favorable
	September 30, 2018			December 31, 2017			(Unfavorable)
Working Capital

Current assets	$	688,894		$	111,173		$	577,721
Current liabilities		17,473,670			13,409,345			(4,064,325	)
Working capital deficit	$	(16,784,776	)	$	(13,298,172	)	$	(3,486,604	)

Long-term debt	$	1,319,528		$	753,192		$	(566,336	)

Stockholders’ deficit	$	(14,081,746	)	$	(9,550,300	)	$	(4,531,446	)

	Nine Months Ended September 30,						Favorable
	2018			2017			(Unfavorable)
Statements of Cash Flows Select Information

Net cash provided (used) by:
Operating activities	$	(2,162,739	)	$	(2,189,196	)	$	26,457
Investing activities	$	(8,969	)	$	-		$	(8,969	)
Financing activities	$	2,746,779		$	2,198,142		$	548,637

	As of				Favorable
	September 30, 2018		December 31, 2017		(Unfavorable)
Balance Sheet Select Information

Cash	$	665,244	$	90,173	$	575,071

Accounts payable and accrued expenses	$	3,179,602	$	2,714,041	$	(465,561	)

Since inception and through September 30, 2018, the Company has raised approximately $13 million in equity and debt transactions. These funds have been used to commence the operations of the Company to acquire and begin the development of its intellectual property portfolio. These activities include attending trade shows and corporate development. Our accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date of these condensed consolidated financial statements. The Company has incurred substantial losses since inception. Its current liabilities exceed its current assets and available cash is not sufficient to fund expected future operations. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Our cash on hand at September 30, 2018 was $665,244. This will be insufficient to fund operations if additional capital is not raised. The Company raised an aggregate of $3,148,500 through the sale of equity and debt securities during the nine months ended September 30, 2018.

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operation.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are a Smaller Reporting Company and are not required to provide the information under this item.

Item 4. Controls and Procedures.

Disclosure of controls and procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below.

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Management has identified the following two material weaknesses which have caused management to conclude that as of September 30, 2018 our disclosure controls and procedures were not effective at the reasonable assurance level:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the quarter ended September 30, 2018. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

Changes in internal controls over financial reporting.

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors.

We are a Smaller Reporting Company (as defined in Rule 12b-2 of the Exchange Act) and are not required to provide the information under this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Number of
Common Shares		Source of
Issued		Payment	Amount
	4,025,000	Services	$	124,775
	24,469,452	Conversion of notes	$	905,675

The above issuances of securities during the three months ended September 30, 2018 were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

Item 3. Defaults upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number		Exhibit Title

31.1		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *		XBRL Instance Document

101.SCH *		XBRL Taxonomy Schema

101.CAL *		XBRL Taxonomy Calculation Linkbase

101.DEF *		XBRL Taxonomy Definition Linkbase

101.LAB *		XBRL Taxonomy Label Linkbase

101.PRE *		XBRL Taxonomy Presentation Linkbase

In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.

* Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 13, 2018	Endonovo Therapeutics, Inc.

	By:	/s/ Alan Collier
		Alan Collier
		Chief Executive Officer (Duly Authorized Officer, Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

Certification of Principal Executive Officer and Principal Financial Officer

Pursuant to 18 U.S.C. 1350

(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Alan Collier, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Endonovo Therapeutics, Inc. for the period ended September 30, 2018;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Dated: November 13, 2018	/s/ Alan Collier
	Chief Executive Officer and Principal Financial Officer

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Endonovo Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Collier, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Alan Collier
	Name: Alan Collier
	Title: Chief Executive Officer and Principal Financial Officer
	Date: November 13, 2018

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

GRAPHIC 4 coverpage-logo_001.jpg begin 644 coverpage-logo_001.jpg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end EX-101.INS 5 endv-20180930.xml XBRL INSTANCE FILE 0001528172 2018-01-01 2018-09-30 0001528172 2016-12-31 0001528172 2017-12-31 0001528172 ENDV:AutosMember 2018-09-30 0001528172 ENDV:MedicalEquipmentMember 2018-09-30 0001528172 ENDV:OtherEquipmentMember 2018-09-30 0001528172 ENDV:AutosMember 2017-12-31 0001528172 ENDV:MedicalEquipmentMember 2017-12-31 0001528172 ENDV:OtherEquipmentMember 2017-12-31 0001528172 2013-02-22 0001528172 ENDV:NotesPayableMember 2016-12-31 0001528172 ENDV:ExecutivesMember 2018-09-30 0001528172 us-gaap:CommonStockMember 2017-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001528172 ENDV:CommonStockSubscriptionReceivableMember 2017-12-31 0001528172 us-gaap:RetainedEarningsMember 2017-12-31 0001528172 ENDV:NotesPayableMember 2017-12-31 0001528172 ENDV:RelatedPartiesMember 2018-09-30 0001528172 ENDV:NonRelatedPartiesMember 2018-09-30 0001528172 ENDV:LockupAgreementMember 2018-01-01 2018-09-30 0001528172 us-gaap:WarrantMember 2017-12-31 0001528172 ENDV:ExecutivesMember 2017-12-31 0001528172 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001528172 ENDV:ConvertibleDebenturesMember 2018-09-30 0001528172 us-gaap:SeriesCPreferredStockMember 2017-12-31 0001528172 us-gaap:SeriesCPreferredStockMember 2018-09-30 0001528172 ENDV:SettlementAgreementMember ENDV:RioGrandeNeurosciencesIncMember 2017-12-01 2017-12-31 0001528172 ENDV:PreferredStockDesignatedMember 2018-09-30 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-07 0001528172 ENDV:SeriesCSecuredRedeemablePreferredStockMember 2017-12-22 0001528172 ENDV:SeriesCSecuredRedeemablePreferredStockMember 2017-12-31 0001528172 ENDV:SeriesCSecuredRedeemablePreferredStockMember srt:MaximumMember 2018-09-30 0001528172 ENDV:SeriesAAMember 2018-09-30 0001528172 ENDV:PreferredStockBMember 2018-09-30 0001528172 ENDV:PreferredStockCMember 2018-09-30 0001528172 ENDV:UndesignatedMember 2018-09-30 0001528172 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2018-01-01 2018-09-30 0001528172 ENDV:WarrantTwoMember 2018-09-30 0001528172 ENDV:WarrantThreeMember 2018-09-30 0001528172 ENDV:WarrantThreeMember us-gaap:SeriesBPreferredStockMember srt:MinimumMember 2018-09-30 0001528172 ENDV:WarrantThreeMember us-gaap:SeriesBPreferredStockMember srt:MaximumMember 2018-09-30 0001528172 ENDV:WarrantThreeMember 2018-01-01 2018-09-30 0001528172 ENDV:NotesPayableMember 2017-01-01 2017-12-31 0001528172 2018-09-30 0001528172 2017-01-01 2017-09-30 0001528172 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-09-30 0001528172 us-gaap:SeriesAPreferredStockMember 2018-09-30 0001528172 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001528172 us-gaap:CommonStockMember 2018-09-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001528172 ENDV:CommonStockSubscriptionReceivableMember 2018-01-01 2018-09-30 0001528172 ENDV:CommonStockSubscriptionReceivableMember 2018-09-30 0001528172 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001528172 us-gaap:RetainedEarningsMember 2018-09-30 0001528172 2017-09-30 0001528172 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-09-30 0001528172 us-gaap:SeriesBPreferredStockMember 2018-09-30 0001528172 ENDV:OneConvertibleDebenturesMember 2018-09-30 0001528172 ENDV:ConvertibleDebenturesMember 2018-01-01 2018-09-30 0001528172 ENDV:FixedRateNoteMember 2018-09-30 0001528172 ENDV:OneFixedRateNoteMember 2018-09-30 0001528172 ENDV:NotesPayableMember 2018-01-01 2018-09-30 0001528172 ENDV:NotesPayableMember 2018-09-30 0001528172 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001528172 us-gaap:WarrantMember 2018-09-30 0001528172 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001528172 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001528172 ENDV:RestrictedCommonStockMember ENDV:OneVariableNoteMember 2018-01-01 2018-09-30 0001528172 ENDV:SeriesAAPreferredStockMember 2018-09-30 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-06 2018-02-07 0001528172 ENDV:SeriesCSecuredRedeemablePreferredStockMember 2018-01-01 2018-09-30 0001528172 ENDV:SeriesCSecuredRedeemablePreferredStockMember 2018-09-30 0001528172 ENDV:WarrantTwoMember 2018-01-01 2018-09-30 0001528172 us-gaap:WarrantMember srt:MinimumMember 2018-09-30 0001528172 us-gaap:WarrantMember srt:MaximumMember 2018-09-30 0001528172 ENDV:WarrantFourMember 2018-09-30 0001528172 ENDV:WarrantFourMember 2018-01-01 2018-09-30 0001528172 ENDV:WarrantFourMember us-gaap:SeriesCPreferredStockMember srt:MinimumMember 2018-09-30 0001528172 ENDV:WarrantFourMember us-gaap:SeriesCPreferredStockMember srt:MaximumMember 2018-09-30 0001528172 ENDV:WarrantFiveMember 2018-01-01 2018-09-30 0001528172 ENDV:WarrantFiveMember 2018-09-30 0001528172 ENDV:ExecutivesMember 2018-01-01 2018-09-30 0001528172 ENDV:PreferredBStockMember 2018-09-30 0001528172 ENDV:PreferredCStockMember 2018-01-01 2018-09-30 0001528172 ENDV:TwoYearWarrantOneMember 2018-01-01 2018-09-30 0001528172 ENDV:TwoYearWarrantOneMember 2018-09-30 0001528172 ENDV:TwoYearWarrantOneMember srt:MinimumMember 2018-09-30 0001528172 ENDV:TwoYearWarrantOneMember srt:MaximumMember 2018-09-30 0001528172 ENDV:SignificantUnobservableInputsLevelThreeMember 2018-01-01 2018-09-30 0001528172 ENDV:SignificantUnobservableInputsLevelThreeMember 2017-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001528172 2018-07-01 2018-09-30 0001528172 2017-07-01 2017-09-30 0001528172 us-gaap:NotesPayableOtherPayablesMember 2018-09-30 0001528172 us-gaap:NotesPayableOtherPayablesMember ENDV:PastMaturityMember 2018-09-30 0001528172 2013-02-21 2013-02-22 0001528172 us-gaap:WarrantMember srt:MinimumMember 2018-01-01 2018-09-30 0001528172 us-gaap:WarrantMember srt:MaximumMember 2018-01-01 2018-09-30 0001528172 ENDV:SignificantUnobservableInputsLevelThreeMember 2018-09-30 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2017-01-01 2017-09-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-01-01 2018-09-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2017-01-01 2017-09-30 0001528172 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2018-09-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2018-09-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2017-09-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2017-09-30 0001528172 us-gaap:ProductMember 2018-01-01 2018-09-30 0001528172 ENDV:GrossRevenueMember 2018-07-01 2018-09-30 0001528172 ENDV:GrossRevenueMember 2018-01-01 2018-09-30 0001528172 ENDV:DistributorPlasticSurgeonsNetMember 2018-07-01 2018-09-30 0001528172 ENDV:DistributorPlasticSurgeonsNetMember 2017-07-01 2017-09-30 0001528172 ENDV:DistributorPlasticSurgeonsNetMember 2017-01-01 2017-09-30 0001528172 ENDV:DistributorPlasticSurgeonsNetMember 2018-01-01 2018-09-30 0001528172 ENDV:DirectSalesPlasticSurgeonsGrossMember 2018-07-01 2018-09-30 0001528172 ENDV:DirectSalesPlasticSurgeonsGrossMember 2017-07-01 2017-09-30 0001528172 ENDV:DirectSalesPlasticSurgeonsGrossMember 2017-01-01 2017-09-30 0001528172 ENDV:DirectSalesPlasticSurgeonsGrossMember 2018-01-01 2018-09-30 0001528172 ENDV:ConvertibleNotesWithVariableConversionRatesMember 2018-09-30 0001528172 ENDV:ConvertibleNotesWithVariableConversionRatesMember ENDV:PastMaturityMember 2018-09-30 0001528172 ENDV:WarrantSixMember 2018-09-30 0001528172 ENDV:WarrantSixMember 2018-01-01 2018-09-30 0001528172 ENDV:WarrantSixMember ENDV:NotesPayableMember srt:MinimumMember 2018-09-30 0001528172 ENDV:WarrantSixMember ENDV:NotesPayableMember srt:MaximumMember 2018-09-30 0001528172 2018-11-08 0001528172 ENDV:FixedRateNoteMember srt:MinimumMember 2018-09-30 0001528172 ENDV:FixedRateNoteMember srt:MaximumMember 2018-09-30 0001528172 ENDV:PastMaturityMember 2018-09-30 0001528172 srt:MinimumMember 2018-09-18 0001528172 srt:MaximumMember 2018-09-18 0001528172 2018-09-18 0001528172 ENDV:RestrictedCommonStockMember ENDV:ThreeVariableNoteMember 2018-01-01 2018-09-30 0001528172 ENDV:RestrictedCommonStockMember ENDV:OneVariableNoteMember srt:MinimumMember 2018-09-30 0001528172 ENDV:RestrictedCommonStockMember ENDV:OneVariableNoteMember srt:MaximumMember 2018-09-30 0001528172 ENDV:RestrictedCommonStockMember 2018-01-01 2018-09-30 0001528172 ENDV:RestrictedCommonStockMember 2018-09-30 0001528172 us-gaap:CommonStockMember ENDV:SubsequentToSeptemberThirtyTwoThousandEighteenMember 2018-09-30 0001528172 ENDV:PreferredCStockMember ENDV:SubsequentToSeptemberThirtyTwoThousandEighteenMember 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ENDONOVO THERAPEUTICS, INC. 10-Q 2018-09-30 false --12-31 Non-accelerated Filer ENDV 55533 90173 665244 64479 4461160 6966896 4212620 1488750 270000 270000 100000 2624984 1175627 0.001 0.0001 100 0.0001 0.0001 0.0001 0.001 1000000 1000000 5000000 50000 8000 1000000 50000 8000 3942000 1000000 5000000 5000 5000 1350 4805600 5000 5000 1350 1318 5000 1350 4805600 5000 316951712 381375857 316951712 381375857 316951712 5000 5000 381375857 1350 600 395129771 1403 -7817953 -12579091 -7817953 -5948196 -6672104 58695192 58695192 575800 9236938 2941176 2373739 1237256 1483285 5870 2367869 1127491 15000 188750 Note 3 – Property, Plant and Equipment   The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Autos</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">64,458</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">64,458</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Medical equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">13,969</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Other equipment</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">8,774</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">8,774</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">87,201</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">78,232</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">79,460</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">77,168</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,741</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,064</td> <td style="line-height: 107%"> </td></tr> </table>   Depreciation expense for the nine months ended September 30, 2018 and 2017 was $2,292 and $11,070, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations. Note 5 - Notes Payable and Long Term Loan   Notes Payable   During the nine months ended September 30, 2018, the Company issued Convertible Notes (“Variable Notes”) totaling $923,870 for funding of $836,000 with original terms of one year and an interest rate of 10%, and a variable conversion rate with discounts of 35% of the Company’s common stock based on the terms included in the Variable Note. The Variable Notes contains a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premiums of 135%. The Company also issued Fixed Rate Notes (“Fixed Rate Notes”) totaling $1,683,000 for funding of $1,500,000 with original terms of six months and an interest rate ranging from 10% to 12%.   The gross amount of all convertible notes with variable conversion rates outstanding at September 30, 2018 is $4,212,620, of which $1,488,750 is past maturity.   Notes payable to a related party in the aggregate amount of $270,000 were outstanding at September 30, 2018, of which $100,000 is past maturity.   As of September 30, 2018, other notes payable outstanding totaled $3,929,903, of which $1,329,903 is past maturity.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%; line-height: 107%">Notes payable at beginning of period</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">7,356,144</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">3,193,956</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,606,870</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,837,070</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Settlements on note payable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(47,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(95,597</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Repayments of notes payable in cash</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(375,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(96,000</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less amounts converted to stock</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,127,491</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,483,285</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable at end of period</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,412,523</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">7,356,144</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less debt discount</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,175,627</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(2,624,984</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,236,896</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,731,160</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable issued to related parties</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Notes payable issued to non-related parties</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">6,966,896</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,461,160</td> <td style="line-height: 107%"> </td></tr> </table>   The maturity dates on the notes payable are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">Twelve months ending,</td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Non-related parties</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Related parties</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Past due</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2,818,653</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">100,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">2,918,653</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">September 30, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,323,870</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">170,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,493,870</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,142,523</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,412,523</td> <td style="line-height: 107%"> </td></tr> </table> Note 6 - Shareholders’ Deficit   Increase in Authorized Shares   On September 18, 2018, an increase in authorized capital stock from 505,000,000 to 2,505,000,000 became effective, of which 5,000,000 shares shall be Preferred Stock, and 2,500,000,000 shall be Common Stock.   Preferred Stock   The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Shares Outstanding</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Par</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Liquidation</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Authorized</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">at September 30, 2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; line-height: 107%">Series AA</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 18%; text-align: right; line-height: 107%">1,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">5,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.0001</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Preferred Series B</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,350</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">100</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Preferred Series C</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,318</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Undesignated</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,942,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   Series AA Preferred Shares   On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.   Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stock holders will receive no dividends nor any value on liquidation. As of September 30, 2018, there were 5,000 shares of Series AA Preferred stock outstanding.   Series B Convertible Preferred Stock   On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of September 30, 2018, 1,350 shares of Series B and 4,805,600 warrant shares have been issued and are outstanding.   Series C Secured Redeemable Preferred Stock   On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheets as of September 30, 2018 and December 31, 2017. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. As of September 30, 2018, the Company has sold 1,318 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 5,996,546 shares of common stock for consideration of $1,317,500. The warrants resulted in a debt discount of $152,972 and $101,808 at September 30, 2018 and December 31, 2017, respectively, and are recorded as a discount to the preferred stock liability on the consolidated balance sheet.   Common Stock   During the nine months ended September 30, 2018, the Company issued pursuant to a private placement offering 1,561,950 shares of common stock and the same number of warrants for cash of $60,000. The Company also issued 58,695,192 shares of common stock for the conversion of notes and accrued interest in the amount of $1,237,256.   During the nine months ended September 30, 2018, the Company issued 17,003 shares of common stock valued at $1,046 related to the extension of outstanding notes and lock-up agreements.   During the nine months ended September 30, 2018, the Company issued 4,150,000 shares of common stock with a value of $130,235, related to services and fees.   During the nine months ended September 30, 2018, the Company issued 3,387,534 shares of common stock with a value of $116,531 as a commitment to repay a note payable on its stated terms. Since the note was satisfactorily repaid, the shares and commitment fee were rescinded.   The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts.   Stock Options   The balance of all stock options outstanding as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> Average Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> Aggregate Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per Share</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 28%; line-height: 107%">Outstanding at January 1, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">93,203,369</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">0.029</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">3.96</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.030</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.86</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">94,203,369</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.029</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.19</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2,232,620</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">93,286,702</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.029</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.21</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2,210,895</td> <td style="line-height: 107%"> </td></tr> </table>   Warrants   During the nine months ended September 30, 2018, in conjunction with the sale of Common Stock, the Company issued three-year common stock purchase warrants to acquire up to 1,561,950 shares of common stock with exercise prices ranging from $0.0734 to $1.00 per share.   In addition, during the nine months ended September 30, 2018, the Company issued a five-year common stock purchase warrant to acquire up to 2,000,000 shares of common stock valued at $71,521 with an exercise price of $0.05 in conjunction with the issuance of a note payable; three-year common stock purchase warrants to acquire up to 4,805,600 shares of common stock with exercise prices ranging from $0.051 to $1.00 in conjunction with the issuance of Series B preferred stock; two-year common stock purchase warrants to acquire up to 3,271,277 shares of common stock with exercise prices ranging from $0.0250 to $0.0516 in conjunction with the issuance of Series C preferred stock; a 2-year common stock purchase warrant to acquire up to 6,200,000 shares of common stock valued at $380,750 with an exercise price of $0.0001; and two-year common stock purchase warrants to acquire up to 642,157 shares of common stock with exercise prices ranging from $0.0368 to $0.0370 in conjunction with the extension of certain notes payable.   The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td colspan="3" style="text-align: center; line-height: 107%">Nine months ended September 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; line-height: 107%">Expected term</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 25%; text-align: center; line-height: 107%">2 years - 5 years</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0001-$0.0516</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">158%-193%</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.92% to 2.81%</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Forfeitures</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> </table>   A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding Warrants</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted Average</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per Share</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Outstanding at January 1, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">61,807,992</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">0.31</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">18,480,984</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(300,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.81</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">79,988,976</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">79,988,976</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td></tr> </table> Note 7 – Related Party Transactions   One executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from related parties at September 30, 2018 is $270,000.   As of September 30, 2018 and December 31, 2017, the balance of executives’ deferred compensation is $942,650 and $922,425, respectively.   From time-to-time executives of the Company advance monies to the Company to cover costs. During the nine months ended September 30, 2018, executives advanced $65,000 of funds to the Company and received payments of $87,000 resulting in a $0 balance of short-term advances due to executives at September 30, 2018. The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Autos</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">64,458</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">64,458</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Medical equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">13,969</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Other equipment</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">8,774</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">8,774</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">87,201</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">78,232</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">79,460</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">77,168</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,741</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,064</td> <td style="line-height: 107%"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%; line-height: 107%">Notes payable at beginning of period</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">7,356,144</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">3,193,956</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,606,870</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,837,070</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Settlements on note payable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(47,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(95,597</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Repayments of notes payable in cash</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(375,500</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(96,000</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less amounts converted to stock</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,127,491</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,483,285</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable at end of period</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,412,523</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">7,356,144</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less debt discount</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,175,627</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(2,624,984</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,236,896</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,731,160</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Notes payable issued to related parties</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Notes payable issued to non-related parties</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">6,966,896</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,461,160</td> <td style="line-height: 107%"> </td></tr> </table> 2336000 1562000 375500 96000 96000 375500 308151 2175459 49806 -58197 The maturity dates on the notes payable are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">Twelve months ending,</td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Non-related parties</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Related parties</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Past due</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2,818,653</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">100,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">2,918,653</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">September 30, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,323,870</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">170,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,493,870</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,142,523</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">270,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,412,523</td> <td style="line-height: 107%"> </td></tr> </table> A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding Warrants</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted Average</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per Share</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Outstanding at January 1, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">61,807,992</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">0.31</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">18,480,984</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(300,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.81</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">79,988,976</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">79,988,976</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.28</td> <td style="line-height: 107%"> </td></tr> </table> 2500000000 2500000000 2500000000 Note 1 - Organization and Nature of Business   Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electroceutical™ device.   Basis of Presentation and Principles of Consolidation   The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.   The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.   Going Concern   These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.   Net Income (Loss) per Share   Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.   Accounts Receivable   The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.   Research and Development   Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations.   Recently Issued Accounting Pronouncements   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements.   In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements.   On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements.   In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses.   In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements.   In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2.   In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements.   In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements. Note 9 – Commitments and Contingencies   Legal Matters   The Company may become involved in various legal proceedings in the normal course of business. 17003 1561950 1350 85 135000 1046 134999 1 85000 0.0001 0.0001 4612237 4711452 155000 155000 13409345 17473670 4221 5939600 7057172 20323 2714041 3179602 4612237 4711452 1064 7741 111173 688894 21000 21000 0.0001 0.0001 50000 50000 0 1350 0 1350 -7817953 -12579091 -5948196 -6672104 -4028129 -3958187 -1530847 -953623 -3127215 -3770929 -1035216 -1035628 3163485 3770929 1052210 1035628 1237256 1108321 575071 8946 4221 9263 60000 740250 661305 108658 -970760 -6945434 -3431939 -4544656 130235 1410071 487474 11070 The balance of all stock options outstanding as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> Average Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2"> Aggregate Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per Share</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Term (years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 28%; line-height: 107%">Outstanding at January 1, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">93,203,369</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">0.029</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">3.96</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.030</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.86</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">94,203,369</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.029</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.19</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2,232,620</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercisable at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">93,286,702</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.029</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.21</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2,210,895</td> <td style="line-height: 107%"> </td></tr> </table> 135000 5 2292 11070 78232 64458 13969 8774 64458 5000 8774 87201 77168 79460 0.10 0.10 0.12 1.35 3193956 7356144 8412523 5837070 2606870 -95597 -47500 2624984 101808 1175627 152972 4731160 7236896 270000 270000 4461160 6966896 170000 5323870 5493870 270000 8142523 8412523 60000 P3Y P3Y P3Y P3Y P5Y P2Y P2Y P2Y P2Y 5996546 2000000 4805600 1561950 3271277 6200000 381803 642157 0.05 0.051 1.00 0.0734 1.00 0.0250 0.0516 0.0001 0.0380 0.0470 0.0368 0.0370 0.069 1.00 93286702 61807992 79988976 18480984 -300000 79988976 0.31 0.28 0.20 0.81 0.28 942650 922425 P3Y2M16D 87000 11500 87000 923870 836000 1683000 1500000 Note 10 – Subsequent Events   Subsequent to September 30, 2018, an aggregate of 9,236,938 shares of restricted common stock were issued on the conversion of $188,750 of principal and $23,106 of accrued interest pursuant to three Variable Notes.   Subsequent to September 30, 2018, 575,800 shares of restricted common stock were issued on the conversion of $15,000 of principal and $5,153 of accrued interest pursuant to one Fixed Rate Note and issued 3-year warrants for an exercise of up to 575,800 shares of common stock with exercise prices ranging from $0.069 to $1.00.   Subsequent to September 30, 2018, the Company received $85,000 of cash from the issuance of 85 shares of Preferred C Stock and issued two-year warrants for the exercise up to 381,803 shares of common stock with an exercise prices ranging from $0.0380 to $0.0470.   Subsequent to September 30, 2018, 1,000,000 shares of restricted common stock were issued related to services rendered.   Subsequent to September 30, 2018, 2,941,176 shares of restricted common stock were issued on the conversion of 750 shares of Preferred B Stock at a conversion rate of $0.0255 per common share.   As a result of these issuances, the total number of common shares outstanding is 395,129,771. Preferred B shares outstanding is 600 and Preferred C shares outstanding is 1,403. 122445 27022 0001528172 93203369 94203369 1000000 0.029 0.029 P3Y2M8D 395129771 598192 1164528 101808 152972 65000 12650 -156321 4500000 Note 4 – Patents   In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Patents</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">4,500,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">4,500,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">485,183</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,014,817</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,500,000</td> <td style="line-height: 107%"> </td></tr> </table>   Amortization expense associated with patents was $485,183 and $0 for the nine months ended September 30, 2018 and 2017. The estimated future amortization expense related to patents as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">Twelve Months Ending September 30,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; padding-left: 10pt; line-height: 107%">2019</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">646,910</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">2023</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Thereafter</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">780,267</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,014,817</td> <td style="line-height: 107%"> </td></tr> </table> The estimated future amortization expense related to patents as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">Twelve Months Ending September 30,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; padding-left: 10pt; line-height: 107%">2019</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">646,910</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">2023</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">646,910</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Thereafter</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">780,267</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,014,817</td> <td style="line-height: 107%"> </td></tr> </table> The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number of Shares Outstanding</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Par</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Liquidation</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Authorized</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">at September 30, 2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; line-height: 107%">Series AA</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 18%; text-align: right; line-height: 107%">1,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">5,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">0.0001</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Preferred Series B</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,350</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">100</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Preferred Series C</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,318</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.0001</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Undesignated</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,942,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table> 163073 115159 5238 75346 100000 2818653 2918653 14162537 18793198 -4690738 -8808162 -4912980 -5636476 -2162739 -2189196 -8969 2746779 2198142 4500000 4500000 4500000 4014817 2024 71521 380750 100 1000 5153 23106 3148500 1000 20.00 Patent portfolio is amortized through 2024 Q3 2650 41132 21306 623917 2465912 61912 289675 66367 8969 2650 2. Revenue Recognition   Contracts with Customers   We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.   We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price.   Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.   In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.   During the three months ended September 30, 2018, we recognized gross revenue of $21,306 from products we sold as a principal in the transaction. During the nine months ended September 30, 2018, we recognized net revenue of $17,045 from products with a selling price of $43,196 and gross revenue of $24,087 from products we sold as a principal in the transaction.   Sources of Revenue   We have identified the following revenues disaggregated by revenue source:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif">1.</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">Plastic Surgeons</td></tr> </table>   As of September 30, 2018 and 2017 the sources of revenue were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Three Months Ended</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Distributor- Plastic surgeons, net</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">17,045</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Direct sales- Plastic surgeons, gross</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,306</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total sources of revenue</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">21,306</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">41,132</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   Warranty   Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.   Significant Judgments in the Application of the Guidance in ASC 606   There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.   We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.   Practical Expedients   Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.   Taxes Collected from Customers   Taxes collected on the value of transaction revenue are excluded from product revenues and are accrued in current liabilities until remitted to governmental authorities.   Effective Date and Transition Disclosures   Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements. Note 8 – Fair Value Measurements   The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended September 30,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Expected term</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 18%; text-align: center; line-height: 107%">1 month - 1 year</td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 2%; text-align: center; line-height: 107%"> </td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 17%; text-align: center; line-height: 107%">1 month - 1 year</td> <td style="width: 1%; text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0129-$0.0326</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0085-$0.0385</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">119%-195%</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">189%-201%</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.79% to 2.59%</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.03% to 1.31%</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Forfeitures</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td></tr> </table>   The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.   The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.   The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Derivative</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Liability</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 75%; line-height: 107%">Balance December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 21%; text-align: right; line-height: 107%">5,939,600</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Issuance of convertible debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,459,645</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Settlements by debt settlement</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(1,312,833</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Change in estimated fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">970,760</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td></tr> </table>   Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.   The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:   Level 1: uses quoted market prices in active markets for identical assets or liabilities.   Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.   Level 3: uses unobservable inputs that are not corroborated by market data.   The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.   The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018:    <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Fair Value Measurements Using</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Quoted Prices in</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Significant Other</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Significant</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Active Markets for</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Observable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Unobservable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Identical Assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Inputs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Inputs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 1)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 2)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 3)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">As of September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 22%; padding-left: 10pt; line-height: 107%">Derivative liability</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,057,172</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,057,172</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td></tr> </table> Basis of Presentation and Principles of Consolidation   The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.   The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern   These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies. Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Net Income (Loss) per Share   Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Accounts Receivable   The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed. Research and Development   Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations. Recently Issued Accounting Pronouncements   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements.   In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements.   On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements.   In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses.   In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements.   In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2.   In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements.   In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.   The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements. The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td colspan="3" style="text-align: center; line-height: 107%">Nine months ended September 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; line-height: 107%">Expected term</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 25%; text-align: center; line-height: 107%">2 years - 5 years</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0001-$0.0516</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">158%-193%</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.92% to 2.81%</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Forfeitures</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> </table> The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine months ended September 30,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Expected term</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 18%; text-align: center; line-height: 107%">1 month - 1 year</td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 2%; text-align: center; line-height: 107%"> </td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 17%; text-align: center; line-height: 107%">1 month - 1 year</td> <td style="width: 1%; text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercise price</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0129-$0.0326</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">$0.0085-$0.0385</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">119%-195%</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">189%-201%</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.79% to 2.59%</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">1.03% to 1.31%</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Forfeitures</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">None</td> <td style="text-align: center; line-height: 107%"> </td></tr> </table> The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Derivative</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Liability</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 75%; line-height: 107%">Balance December 31, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 21%; text-align: right; line-height: 107%">5,939,600</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Issuance of convertible debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,459,645</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Settlements by debt settlement</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(1,312,833</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Change in estimated fair value</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">970,760</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td></tr> </table> The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018:    <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Fair Value Measurements Using</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Quoted Prices in</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Significant Other</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Significant</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Active Markets for</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Observable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Unobservable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Identical Assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Inputs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Inputs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 1)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 2)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Level 3)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Total</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">As of September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 22%; padding-left: 10pt; line-height: 107%">Derivative liability</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,057,172</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,057,172</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,057,172</td> <td style="line-height: 107%"> </td></tr> </table> The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Patents</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">4,500,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">4,500,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">485,183</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,014,817</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4,500,000</td> <td style="line-height: 107%"> </td></tr> </table> As of September 30, 2018 and 2017 the sources of revenue were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Three Months Ended</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Distributor- Plastic surgeons, net</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">17,045</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Direct sales- Plastic surgeons, gross</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">21,306</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">24,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total sources of revenue</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">21,306</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">41,132</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table> 485183 0 0.029 0.030 P3Y11M15D 0 P2Y P5Y 0.0001 0.0516 0.00 0.75 0.00 7057172 5939600 7057172 7057172 1459645 970760 1.50 1318 1317500 65000 2018 43196 -9550300 31692 19604016 -1570 -29184443 5 -14081746 5 38136 22884078 -1570 -37002396 1 60000 156 59844 1561950 130235 416 129819 4150000 4150000 1000000 1046 2 1044 17003 113076 113076 71521 71521 485183 3929903 1329903 1.58 1.93 0.0192 0.0281 7057172 7057172 1312833 P1M P1M P1Y P1Y 1.19 1.89 1.95 2.01 0.00 0.00 0.0179 0.0103 0.0259 0.0131 0.00 0.00 0.0129 0.0326 0.0085 0.0385 4862 4312 36270 16994 617500 82000 19417 19417 116531 3387534 0 0 41132 21306 17045 21306 24087 17045 21306 24087 0.35 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. true true true 5 5 1 31692 38136 19604016 22884078 1570 1570 -29184443 -37002396 80000 80000 -0.02 -0.06 -0.02 -0.03 348379894 220353026 369234308 263535090 2647939 1467888 382473 37950 1467311 382473 382473 646910 646910 646910 646910 646910 780267 505000000 2505000000 2232620 2210895 P1Y10M10D 750 0.0255 EX-101.SCH 6 endv-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Patents link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable and Long Term Loan link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Nature of Business (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Patents (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Notes Payable and Long Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Shareholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Organization and Nature of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Patents (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Patents - Schedule of Patents Less Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Patents - Schedule of Estimated Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable and Long Term Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Shareholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Shareholders' Deficit - Schedule of Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Shareholders' Deficit - Schedule of Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Shareholders' Deficit - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 endv-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 endv-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 endv-20180930_lab.xml XBRL LABEL FILE Property, Plant and Equipment, Type [Axis] Autos [Member] Medical Equipment [Member] Other Equipment [Member] Debt Instrument [Axis] Notes Payable [Member] Related Party [Axis] Executives [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Common Stock Subscription Receivable [Member] Retained Earnings [Member] Related Parties [Member] Non-Related Parties [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Lock-Up Agreement [Member] Warrant [Member] Class of Stock [Axis] Series AA Preferred Stock [Member] Convertible Debentures [Member] Series C Preferred Stock [Member] Settlement Agreement [Member] Legal Entity [Axis] Rio Grande Neurosciences, Inc. [Member] Preferred Stock Designated [Member] Series B Convertible Preferred Stock [Member] Series C Secured Redeemable Preferred Stock [Member] Range [Axis] Maximum [Member] Series AA [Member] Preferred Stock B [Member] Preferred Stock C [Member] Undesignated [Member] Sale of Stock [Axis] Private Placement [Member] Warrant Two [Member] Warrant Three [Member] Minimum [Member] One Convertible Debentures [Member] Fixed Rate Note [Member] One Fixed Rate Note [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Award Type [Axis] Restricted Common Stock [Member] One Variable Note [Member] Series AA Preferred Stock [Member] Warrant Four [Member] Warrant Five [Member] Preferred B Stock [Member] Preferred C Stock [Member] Two Year Warrant One [Member] Financial Instrument [Axis] Significant Unobservable Inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Other Notes Payable [Member] Past Maturity [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Exercise Price [Member] Product and Service [Axis] Product [Member] Gross Revenue [Member] Distributor - Plastic Surgeons Net [Member] Direct Sales - Plastic Surgeons Gross [Member] Convertible Notes With Variable Conversion Rates [Member] Warrant Six [Member] Three Variable Note [Member] Scenario [Axis] Subsequent to September 30, 2018 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable Prepaid expenses and other current assets Total current assets Property Plant and Equipment, net Patents, net Total assets LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses Short term advances Notes payable, net of discounts of $1,175,627 as of Septebmer 30, 2018 and $2,624,984 as of December 31, 2017 Notes payable - related parties Derivative liability Current portion of long term loan Total current liabilities Series C preferred stock liability, net of discounts of $152,972 at September 30, 2018 and $101,808 as of December 31, 2017 Acquisition payable Total liabilities COMMITMENTS AND CONTINGENCIES, note 9 Shareholders' deficit Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at September 30, 2018 and December 31, 2017 Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at September 30, 2018 and December 31, 2017 Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 381,375,857 and 316,951,712 shares issued and outstanding as of Septermber 30, 2018 and December 31, 2017 Additional paid-in capital Stock subscriptions Accumulated deficit Total shareholders' deficit Total liabilities and shareholders' deficit Statement [Table] Statement [Line Items] Discounts on current notes payable Series C preferred stock liability, net of discounts Super AA super voting preferred stock, par value Super AA super voting preferred stock, shares authorized Super AA super voting preferred stock, shares issued Super AA super voting preferred stock, shares outstanding Series B convertible preferred stock, par value Series B convertible preferred stock, shares authorized Series B convertible preferred stock, shares issued Series B convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Loss from operations Other income (expense) Change in fair value of derivative liability Gain (loss) on settlement of debt Settlement expenses Interest expense, net Other income (expense) Loss before income taxes Provision for income taxes Net loss Basic and diluted loss per share Weighted average common shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Operating activities: Net loss Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization expense Fair value of shares issued for services Gain on extinguishment of debt Amortization of note discount and original issue discount Amortization of discount on Series C Preferred stock liability Non-cash interest expense Non-cash value of warrant and stock options issued for services Change in fair value of derivative liability Changes in assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable and accrued expenses Net cash used in operating activities Investing activities: Acquisition of property and equipment Net cash used in investing activities Financing activities: Proceeds from the issuance of notes payable Proceeds from related party short-term advances Repayments on related parties short term advances Proceeds from issuance of preferred stock Proceeds from issuance of common stock and units Payment against long term loan Payment against notes payable Proceeds from issuance of redeemable shares Net cash provided by financing activities Net increase in cash Cash, beginning of year Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for Preferred C dividends Cash paid for income taxes Non Cash Investing and Financing Activities: Conversion of notes payable and accrued interest to common stock Reduction in note payable and accrued interest as result of settlement Common stock issued on settlement of debt Notes payable and accrued interest exchanged for common stock units Value of stock options granted in satisfaction of deferred compensation Balance Balance, shares Private placement units issued for cash Private placement units issued for cash, shares Preferred stock issued for cash Preferred stock issued for cash, shares Share issued for services Share issued for services, shares Shares issued with lock-up agreements Shares issued with lock-up agreements, shares Shares issued for conversion of notes payable and accrued interest Shares issued for conversion of notes payable and accrued interest, shares Valuation of warrants issued with Preferred Series C Valuation of warrant and stock options issued for services Valuation of warrants issued with note payable Valuation of warrants issued for extension of notes Balance Balance, shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Business Revenue Recognition [Abstract] Revenue Recognition Property, Plant and Equipment [Abstract] Property, Plant and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Patents Debt Disclosure [Abstract] Notes Payable and Long Term Loan Equity [Abstract] Shareholders' Deficit Related Party Transactions [Abstract] Related Party Transactions Fair Value Disclosures [Abstract] Fair Value Measurements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Principles of Consolidation Going Concern Use of Estimates Net Income (Loss) Per Share Accounts Receivable Research and Development Recently Issued Accounting Pronouncements Schedule of Disaggregated by Revenue Source Summary of Property, Plant and Equipment Schedule of Patents Less Accumulated Amortization Schedule of Estimated Future Amortization Expense Schedule of Notes Payable Schedule of Maturity Dates of Notes Payable Schedule of Preferred Stock Schedule of Stock Options Outstanding Schedule of Stock Options Valuation of Assumptions Schedule of Warrants Outstanding Schedule of Stock Option Valuation Assumptions Schedule of Changes in Liabilities with Significant Unobservable Inputs Schedule of Balance in Liabilities with Significant Unobservable Inputs Debt and equity financing Provision for doubtful accounts Research and development expenses Recognized net revenues Selling price Total sources of revenue Depreciation expense Property, Plant and Equipment, gross Less accumulated depreciation Property, Plant and Equipment, net Acquisition of patents Patents expire period Patent amortization description Amortization expense Patents Less accumulated amortization Total 2019 2020 2021 2022 2023 Thereafter Convertible debentures outstanding amount Debt instrument, interest rates Debt conversion, converted instrument, rates Percentage of issuance note of premium Note payable outstanding Note payable related parties Other notes payable outstanding Payments for notes payable Notes payable at beginning of period Notes payable issued Settlements on note payable Repayments of notes payable in cash Less amounts converted to stock Notes payable at end of period Less debt discount Note payable, net Notes payable issued to related parties Notes payable issued to non-related parties Extinguishment of Debt [Axis] Past due June 30, 2019 Total Capital stock authorized Preferred stock, authorized Preferred stock, par value Preferred stock voting rights Preferred stock, outstanding Stated value dividend Warrants term Share exercise price Preferred stock, shares issued Preferred stock dividend per share Shares issued, price per share Sale of stock for preferred stock Warrants issued to purchase common stock Sale of stock, consideration Debt discount Common stock, shares issued Number of warrants issued for cash Issuance of common stock, value Issuance of common stock related to services and fees, shares Issuance of common stock related to services and fees Shares issued for commitment fees, shares Shares issued for commitment fees Warrant exercise price Warrant value Number of Shares Authorized Number of Shares Outstanding Par Value Liquidation Value Stock Option Outstanding, Beginning Balance Stock Option Outstanding, Granted Stock Option Outstanding, Cancelled Stock Option Outstanding, Exercised Stock Option Outstanding, Ending Balance Stock Option Outstanding, Exercisable Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Exercisable Weighted Average Remaining Contractual Term (years), Outstanding Beginning Weighted Average Remaining Contractual Term (years), Granted Weighted Average Remaining Contractual Term (years), Outstanding Ending Weighted Average Remaining Contractual Term (years), Exercisable Aggregated Intrinsic Value, Outstanding Aggregated Intrinsic Value, Exercisable Expected term Exercise price Expected volatility Expected dividends Risk-free interest rate Forfeitures Shares Outstanding, Beginning Balance Shares, Granted Shares, Cancelled Shares, Exercised Shares Outstanding, Ending Balance Shares Exercisable, Ending Balance Weighted-Average Exercise Price, Outstanding Beginning Balance Weighted-Average Exercise Price, Granted Weighted average exercise price, Cancelled Weighted-Average Exercise Price, Exercised Weighted-Average Exercise Price, Outstanding Ending Balance Weighted-Average Exercise Price, Exercisable Ending Balance Deferred compensation Related party advances Repayment of related party debt Short-term advances Fair value assumptions, measurement input, term Fair value assumptions, measurement input, exercise price Fair value assumptions, measurement input, percentage Forfeitures Derivative Liability, beginning Issuance of convertible debt Settlements by debt settlement Change in estimated fair value Derivative Liability, ending Derivative liability Total Issuance of restricted common stock, shares Issuance of restricted common stock, value Accrued interest Number of shares issued, value Number of shares issued Warrant to purchase common stock Number of shares issued for services Conversion of shares converted Conversion rate price per share Number of shares outstanding The amount of acquisition payable. Amortization of discount on Preferred stock liability. Autos [Member] Change in estimated fair value. Common stock issued on settlement of debt. Common Stock Subscription Receivable [Member] The amount of Conversion of notes payable and accrued interest to common stock in a noncash (or part noncash) transaction. Convertible Debentures [Member] Convertible Preferred, Stock Par Value. Convertible Preferred Stock, Shares Authorized Convertible Preferred Stock, Shares Issued. Convertible Preferred Stock, Shares Outstanding. Converible Preferred Stock, Value. debt and equity financing. Executives [Member] Fair value assumptions forfeiture rate. Fair value assumptions, measurement input, exercise price. Fair value assumptions, measurement input, percentage. Fair value assumptions, measurement input, term. Fixed Rate Note [Member] Going concern [Policy Text Block] Lock-Up Agreement [Member] Past due. Medical Equipment [Member] Non-Related Parties [Member] Non-cash interest expense. Notes payable and accrued interest exchanged for common stock units. Notes payable issued to non-related parties. Notes Payable [Member] Number of warrants issued for cash. One Convertible Debentures [Member] One Fixed Rate Note [Member] One Variable Note [Member] Other Equipment [Member] Past Maturity [Member] Patent amortization description. Patents expire period. Percentage of issuance note of premium. Preferred B Stock [Member] Preferred C Stock [Member] Preferred Stock B [Member] Preferred Stock C [Member] Preferred Stock Designated [Member] Private placement units issued for cash. Private placement units issued for cash, shares. Related Parties [Member] Restricted Common Stock [Member] Revenue recognition [Text Block] Rio Grande Neurosciences, Inc. [Member] Schedule of Balance in Liabilities with Significant Unobservable Inputs [Table Text Block] Schedule of preferred stock [Table Text Block] Series AA [Member] Series AA Preferred Stock [Member] Series C Secured Redeemable Preferred Stock [Member] Settlement Agreement [Member] Settlements on note payable. The forfeitures rate assumption that is used in valuing an option on its own shares. Share based compensation arrangement by share based payment award non option equity exercisable. Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option outstanding weighted average number of share. Share based compensation arrangement by share based paymet award non option weighted average exercisable. Share exercise price, percentage. Weighted average remaining contractual term (years), beginning outstanding. Shares issued with lock-up agreements. Shares issued with lock-up agreements, shares. Significant Unobservable Inputs (Level 3) [Member] Two Year Warrant One [Member] Two Year Warrant Two [Member] Undesignated [Member] Valuation of warrants issued with note payable. Valuation of warrants issued with preferred stock. Variable Notes [Member] Warrant Five [Member] Warrant Four [Member] Warrant Three [Member] Warrant 2 [Member] Warrants term. Shares issued for commitment fees. Shares issued for commitment fees, shares. Valuation of warrants issued for extension of notes. Gross Revenue [Member] Distributor Plastic Surgeons Net [Member] Direct Sales Plastic Surgeons Gross [Member] Convertible Notes With Variable Conversion Rates [Member] Warrant Six [Member] Convertible Note on August 3, 2019 [Member] Value of stock options granted in satisfaction of deferred compensation. Non-cash value of warrant and stock options issued for services. Valuation of warrant and stock options issued for services. Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Three Variable Note [Member] Subsequent to September 30, 2018 [Member] SeriesAAPreferredStockMember Assets, Current Assets Liabilities, Current Liabilities Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Litigation Settlement, Expense Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Bank Debt Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Finite-Lived Intangible Assets, Gross Notes Payable Notes and Loans Payable Notes Payable, Related Parties Percent of upfront license fee paid to ACSC Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Series B preferred stock dividend payable in common stock ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable FairValueAssumptionsForfeitureRate Derivative Liability Extinguishment of Debt, Amount Financial Liabilities Fair Value Disclosure EX-101.PRE 10 endv-20180930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2018

Nov. 08, 2018

Document And Entity Information

Entity Registrant Name ENDONOVO THERAPEUTICS, INC.

Entity Central Index Key 0001528172

Document Type 10-Q

Document Period End Date Sep. 30, 2018

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Small Business Flag true

Entity Emerging Growth Company true

Entity Ex Transition Period true

Entity Common Stock, Shares Outstanding 395,129,771

Trading Symbol ENDV

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2018

X

- References
No definition available.
+ Details

Name: ENDV_DocumentAndEntityInformationAbstract

Namespace Prefix: ENDV_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Current assets:

Cash $ 665,244 $ 90,173

Accounts receivable 2,650

Prepaid expenses and other current assets 21,000 21,000

Total current assets 688,894 111,173

Property Plant and Equipment, net 7,741 1,064

Patents, net 4,014,817 4,500,000

Total assets 4,711,452 4,612,237

Current Liabilities

Accounts payable and accrued expenses 3,179,602 2,714,041

Short term advances 20,323

Notes payable, net of discounts of $1,175,627 as of Septebmer 30, 2018 and $2,624,984 as of December 31, 2017 6,966,896 4,461,160

Notes payable - related parties 270,000 270,000

Derivative liability 7,057,172 5,939,600

Current portion of long term loan 4,221

Total current liabilities 17,473,670 13,409,345

Series C preferred stock liability, net of discounts of $152,972 at September 30, 2018 and $101,808 as of December 31, 2017 1,164,528 598,192

Acquisition payable 155,000 155,000

Total liabilities 18,793,198 14,162,537

COMMITMENTS AND CONTINGENCIES, note 9

Shareholders' deficit

Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at September 30, 2018 and December 31, 2017 5 5

Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at September 30, 2018 and December 31, 2017 1

Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 381,375,857 and 316,951,712 shares issued and outstanding as of Septermber 30, 2018 and December 31, 2017 38,136 31,692

Additional paid-in capital 22,884,078 19,604,016

Stock subscriptions (1,570) (1,570)

Accumulated deficit (37,002,396) (29,184,443)

Total shareholders' deficit (14,081,746) (9,550,300)

Total liabilities and shareholders' deficit $ 4,711,452 $ 4,612,237

X

- Definition
The amount of acquisition payable.
+ References
No definition available.
+ Details

Name: ENDV_AcquisitionPayable

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Converible Preferred Stock, Value.
+ References
No definition available.
+ Details

Name: ENDV_ConvertiblePreferredStockValue

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of subscription receivable from investors who have been allocated common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Discounts on current notes payable $ 1,175,627 $ 2,624,984

Super AA super voting preferred stock, par value $ 0.001 $ 0.001

Super AA super voting preferred stock, shares authorized 1,000,000 1,000,000

Super AA super voting preferred stock, shares issued 5,000 5,000

Super AA super voting preferred stock, shares outstanding 5,000 5,000

Series B convertible preferred stock, par value $ 0.0001 $ 0.0001

Series B convertible preferred stock, shares authorized 50,000 50,000

Series B convertible preferred stock, shares issued 1,350 0

Series B convertible preferred stock, shares outstanding 1,350 0

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 2,500,000,000 2,500,000,000

Common stock, shares issued 381,375,857 316,951,712

Common stock, shares outstanding 381,375,857 316,951,712

Series C Preferred Stock [Member]

Series C preferred stock liability, net of discounts $ 152,972 $ 101,808

X

- Definition
Convertible Preferred, Stock Par Value.
+ References
No definition available.
+ Details

Name: ENDV_ConvertiblePreferredStockParValue

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Convertible Preferred Stock, Shares Authorized
+ References
No definition available.
+ Details

Name: ENDV_ConvertiblePreferredStockSharesAuthorized

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Convertible Preferred Stock, Shares Issued.
+ References
No definition available.
+ Details

Name: ENDV_ConvertiblePreferredStockSharesIssued

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Convertible Preferred Stock, Shares Outstanding.
+ References
No definition available.
+ Details

Name: ENDV_ConvertiblePreferredStockSharesOutstanding

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Income Statement [Abstract]

Revenue $ 21,306 $ 41,132

Cost of revenue 4,312 4,862

Gross profit 16,994 36,270

Operating expenses 1,052,210 1,035,628 3,163,485 3,770,929

Loss from operations (1,035,216) (1,035,628) (3,127,215) (3,770,929)

Other income (expense)

Change in fair value of derivative liability (3,431,939) (4,544,656) (970,760) (6,945,434)

Gain (loss) on settlement of debt 49,806 (58,197) 308,151 2,175,459

Settlement expenses (80,000) (80,000)

Interest expense, net (1,530,847) (953,623) (4,028,129) (3,958,187)

Other income (expense) (4,912,980) (5,636,476) (4,690,738) (8,808,162)

Loss before income taxes (5,948,196) (6,672,104) (7,817,953) (12,579,091)

Provision for income taxes

Net loss $ (5,948,196) $ (6,672,104) $ (7,817,953) $ (12,579,091)

Basic and diluted loss per share $ (0.02) $ (0.03) $ (0.02) $ (0.06)

Weighted average common shares outstanding:

Basic and diluted 369,234,308 263,535,090 348,379,894 220,353,026

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4CC
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Operating activities:

Net loss $ (7,817,953) $ (12,579,091)

Adjustments to reconcile net loss to cash used in operating activities:

Depreciation and amortization expense 487,474 11,070

Fair value of shares issued for services 130,235 1,410,071

Gain on extinguishment of debt (308,151) (2,175,459)

Amortization of note discount and original issue discount 2,647,939 1,467,888

Amortization of discount on Series C Preferred stock liability 61,912

Non-cash interest expense 623,917 2,465,912

Non-cash value of warrant and stock options issued for services 382,473

Change in fair value of derivative liability 970,760 6,945,434

Changes in assets and liabilities:

Accounts receivable (2,650)

Prepaid expenses and other current assets 156,321

Accounts payable and accrued expenses 661,305 108,658

Net cash used in operating activities (2,162,739) (2,189,196)

Investing activities:

Acquisition of property and equipment (8,969)

Net cash used in investing activities (8,969)

Financing activities:

Proceeds from the issuance of notes payable 2,336,000 1,562,000

Proceeds from related party short-term advances 65,000 12,650

Repayments on related parties short term advances (87,000) (11,500)

Proceeds from issuance of preferred stock 135,000 5

Proceeds from issuance of common stock and units 60,000 740,250

Payment against long term loan (4,221) (9,263)

Payment against notes payable (375,500) (96,000)

Proceeds from issuance of redeemable shares 617,500

Net cash provided by financing activities 2,746,779 2,198,142

Net increase in cash 575,071 8,946

Cash, beginning of year 90,173 55,533

Cash, end of period 665,244 64,479

Supplemental disclosure of cash flow information:

Cash paid for interest 122,445 27,022

Cash paid for Preferred C dividends 37,950

Cash paid for income taxes

Non Cash Investing and Financing Activities:

Conversion of notes payable and accrued interest to common stock 1,237,256 1,108,321

Reduction in note payable and accrued interest as result of settlement 82,000

Common stock issued on settlement of debt 289,675

Notes payable and accrued interest exchanged for common stock units 66,367

Value of stock options granted in satisfaction of deferred compensation $ 1,467,311

X

- Definition
Amortization of discount on Preferred stock liability.
+ References
No definition available.
+ Details

Name: ENDV_AmortizationOfDiscountPreferredStockLiability

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Common stock issued on settlement of debt.
+ References
No definition available.
+ Details

Name: ENDV_CommonStockIssuedOnSettlementOfDebt

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of Conversion of notes payable and accrued interest to common stock in a noncash (or part noncash) transaction.
+ References
No definition available.
+ Details

Name: ENDV_ConversionOfNotesPayableAndAccruedInterestToCommonStock

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Non-cash interest expense.
+ References
No definition available.
+ Details

Name: ENDV_NoncashExpensesPaidInDebtIssuance

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Non-cash value of warrant and stock options issued for services.
+ References
No definition available.
+ Details

Name: ENDV_NoncashValueOfWarrantAndStockOptionsIssuedForServices

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Notes payable and accrued interest exchanged for common stock units.
+ References
No definition available.
+ Details

Name: ENDV_NotesPayableAndAccruedInterestExchangedForCommonStockUnits

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock options granted in satisfaction of deferred compensation.
+ References
No definition available.
+ Details

Name: ENDV_ValueOfStockOptionsGrantedInSatisfactionOfDeferredCompensation

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4CC
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_DividendsPreferredStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of notes assumed in noncash investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_NotesAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stock that is classified as callable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to settle a bank borrowing during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)

Series AA Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Common Stock Subscription Receivable [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2017 $ 5 $ 31,692 $ 19,604,016 $ (1,570) $ (29,184,443) $ (9,550,300)

Balance, shares at Dec. 31, 2017 5,000 316,951,712

Private placement units issued for cash $ 156 59,844 60,000

Private placement units issued for cash, shares 1,561,950

Preferred stock issued for cash $ 1 134,999 135,000

Preferred stock issued for cash, shares 1,350

Share issued for services $ 416 129,819 $ 130,235

Share issued for services, shares 4,150,000 4,150,000

Shares issued with lock-up agreements $ 2 1,044 $ 1,046

Shares issued with lock-up agreements, shares 17,003

Shares issued for conversion of notes payable and accrued interest $ 5,870 2,367,869 2,373,739

Shares issued for conversion of notes payable and accrued interest, shares 58,695,192

Valuation of warrants issued with Preferred Series C 113,076 113,076

Valuation of warrant and stock options issued for services 382,473 382,473

Valuation of warrants issued with note payable 71,521 71,521

Valuation of warrants issued for extension of notes 19,417 19,417

Net loss (7,817,953) (7,817,953)

Balance at Sep. 30, 2018 $ 5 $ 1 $ 38,136 $ 22,884,078 $ (1,570) $ (37,002,396) $ (14,081,746)

Balance, shares at Sep. 30, 2018 5,000 1,350 381,375,857

X

- Definition
Valuation of warrants issued for extension of notes.
+ References
No definition available.
+ Details

Name: ENDV_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForExtensionOfNotes

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Private placement units issued for cash.
+ References
No definition available.
+ Details

Name: ENDV_PrivatePlacementUnitsIssuedForCash

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Private placement units issued for cash, shares.
+ References
No definition available.
+ Details

Name: ENDV_PrivatePlacementUnitsIssuedForCashShares

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued with lock-up agreements.
+ References
No definition available.
+ Details

Name: ENDV_SharesIssuedWithLockupAgreements

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares issued with lock-up agreements, shares.
+ References
No definition available.
+ Details

Name: ENDV_SharesIssuedWithLockupAgreementsShares

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Valuation of warrant and stock options issued for services.
+ References
No definition available.
+ Details

Name: ENDV_ValuationOfWarrantAndStockOptionsIssuedForServices

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Valuation of warrants issued with note payable.
+ References
No definition available.
+ Details

Name: ENDV_ValuationOfWarrantsIssuedWithNotePayable

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Valuation of warrants issued with preferred stock.
+ References
No definition available.
+ Details

Name: ENDV_ValuationOfWarrantsIssuedWithPreferredStock

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1

Organization and Nature of Business
9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Business

Note 1 - Organization and Nature of Business

Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electroceutical™ device.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.

Going Concern

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

Net Income (Loss) per Share

Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

Accounts Receivable

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.

Research and Development

Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements.

In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements.

On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements.

In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2.

In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements.

In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Recognition
9 Months Ended

Sep. 30, 2018

Revenue Recognition [Abstract]

Revenue Recognition

2. Revenue Recognition

Contracts with Customers

We have adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2018 using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for 2018 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.

We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

During the three months ended September 30, 2018, we recognized gross revenue of $21,306 from products we sold as a principal in the transaction. During the nine months ended September 30, 2018, we recognized net revenue of $17,045 from products with a selling price of $43,196 and gross revenue of $24,087 from products we sold as a principal in the transaction.

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

1. Plastic Surgeons

As of September 30, 2018 and 2017 the sources of revenue were as follows:

Three Months Ended Nine Months Ended

September 30, September 30,

2018 2017 2018 2017

Distributor- Plastic surgeons, net $ - $ - $ 17,045 $ -

Direct sales- Plastic surgeons, gross 21,306 - 24,087 -

Total sources of revenue $ 21,306 $ - $ 41,132 $ -

Warranty

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

Significant Judgments in the Application of the Guidance in ASC 606

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Practical Expedients

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Taxes Collected from Customers

Taxes collected on the value of transaction revenue are excluded from product revenues and are accrued in current liabilities until remitted to governmental authorities.

Effective Date and Transition Disclosures

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

X

- Definition
Revenue recognition [Text Block]
+ References
No definition available.
+ Details

Name: ENDV_RevenueRecognitionTextBlock

Namespace Prefix: ENDV_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property, Plant and Equipment
9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Note 3 – Property, Plant and Equipment

The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017:

September 30, December 31,

2018 2017

Autos $ 64,458 $ 64,458

Medical equipment 13,969 5,000

Other equipment 8,774 8,774

87,201 78,232

Less accumulated depreciation 79,460 77,168

$ 7,741 $ 1,064

Depreciation expense for the nine months ended September 30, 2018 and 2017 was $2,292 and $11,070, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

Patents
9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Patents

Note 4 – Patents

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017:

September 30, December 31,

2018 2017

Patents $ 4,500,000 $ 4,500,000

Less accumulated amortization 485,183 -

$ 4,014,817 $ 4,500,000

Amortization expense associated with patents was $485,183 and $0 for the nine months ended September 30, 2018 and 2017. The estimated future amortization expense related to patents as of September 30, 2018 is as follows:

Twelve Months Ending September 30, Amount

2019 $ 646,910

2020 646,910

2021 646,910

2022 646,910

2023 646,910

Thereafter 780,267

Total $ 4,014,817

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1

Notes Payable and Long Term Loan
9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Notes Payable and Long Term Loan

Note 5 - Notes Payable and Long Term Loan

Notes Payable

During the nine months ended September 30, 2018, the Company issued Convertible Notes (“Variable Notes”) totaling $923,870 for funding of $836,000 with original terms of one year and an interest rate of 10%, and a variable conversion rate with discounts of 35% of the Company’s common stock based on the terms included in the Variable Note. The Variable Notes contains a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premiums of 135%. The Company also issued Fixed Rate Notes (“Fixed Rate Notes”) totaling $1,683,000 for funding of $1,500,000 with original terms of six months and an interest rate ranging from 10% to 12%.

The gross amount of all convertible notes with variable conversion rates outstanding at September 30, 2018 is $4,212,620, of which $1,488,750 is past maturity.

Notes payable to a related party in the aggregate amount of $270,000 were outstanding at September 30, 2018, of which $100,000 is past maturity.

As of September 30, 2018, other notes payable outstanding totaled $3,929,903, of which $1,329,903 is past maturity.

September 30, December 31,

2018 2017

Notes payable at beginning of period $ 7,356,144 $ 3,193,956

Notes payable issued 2,606,870 5,837,070

Settlements on note payable (47,500 ) (95,597 )

Repayments of notes payable in cash (375,500 ) (96,000 )

Less amounts converted to stock (1,127,491 ) (1,483,285 )

Notes payable at end of period 8,412,523 7,356,144

Less debt discount (1,175,627 ) (2,624,984 )

$ 7,236,896 $ 4,731,160

Notes payable issued to related parties $ 270,000 $ 270,000

Notes payable issued to non-related parties $ 6,966,896 $ 4,461,160

The maturity dates on the notes payable are as follows:

Twelve months ending, Non-related parties
Related

parties
Total

Past due $ 2,818,653 $ 100,000 $ 2,918,653

September 30, 2019 5,323,870 170,000 5,493,870

Total $ 8,142,523 $ 270,000 $ 8,412,523

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit
9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Shareholders' Deficit

Note 6 - Shareholders’ Deficit

Increase in Authorized Shares

On September 18, 2018, an increase in authorized capital stock from 505,000,000 to 2,505,000,000 became effective, of which 5,000,000 shares shall be Preferred Stock, and 2,500,000,000 shall be Common Stock.

Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

Number of Shares Number of Shares Outstanding Par Liquidation

Authorized at September 30, 2018 Value Value

Series AA 1,000,000 5,000 $ 0.0001 $ -

Preferred Series B 50,000 1,350 $ 0.0001 $ 100

Preferred Series C 8,000 1,318 $ 0.0001 $ 1,000

Undesignated 3,942,000 - - -

Series AA Preferred Shares

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stock holders will receive no dividends nor any value on liquidation. As of September 30, 2018, there were 5,000 shares of Series AA Preferred stock outstanding.

Series B Convertible Preferred Stock

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of September 30, 2018, 1,350 shares of Series B and 4,805,600 warrant shares have been issued and are outstanding.

Series C Secured Redeemable Preferred Stock

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheets as of September 30, 2018 and December 31, 2017. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. As of September 30, 2018, the Company has sold 1,318 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 5,996,546 shares of common stock for consideration of $1,317,500. The warrants resulted in a debt discount of $152,972 and $101,808 at September 30, 2018 and December 31, 2017, respectively, and are recorded as a discount to the preferred stock liability on the consolidated balance sheet.

Common Stock

During the nine months ended September 30, 2018, the Company issued pursuant to a private placement offering 1,561,950 shares of common stock and the same number of warrants for cash of $60,000. The Company also issued 58,695,192 shares of common stock for the conversion of notes and accrued interest in the amount of $1,237,256.

During the nine months ended September 30, 2018, the Company issued 17,003 shares of common stock valued at $1,046 related to the extension of outstanding notes and lock-up agreements.

During the nine months ended September 30, 2018, the Company issued 4,150,000 shares of common stock with a value of $130,235, related to services and fees.

During the nine months ended September 30, 2018, the Company issued 3,387,534 shares of common stock with a value of $116,531 as a commitment to repay a note payable on its stated terms. Since the note was satisfactorily repaid, the shares and commitment fee were rescinded.

The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts.

Stock Options

The balance of all stock options outstanding as of September 30, 2018 is as follows:

Weighted Weighted Average

Average

Exercise Price
Remaining Contractual
Aggregate

Intrinsic

Options Per Share Term (years) Value

Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96

Granted 1,000,000 $ 0.030 1.86

Cancelled - $ - -

Exercised - $ - -

Outstanding at September 30, 2018 94,203,369 $ 0.029 3.19 $ 2,232,620

Exercisable at September 30, 2018 93,286,702 $ 0.029 3.21 $ 2,210,895

Warrants

During the nine months ended September 30, 2018, in conjunction with the sale of Common Stock, the Company issued three-year common stock purchase warrants to acquire up to 1,561,950 shares of common stock with exercise prices ranging from $0.0734 to $1.00 per share.

In addition, during the nine months ended September 30, 2018, the Company issued a five-year common stock purchase warrant to acquire up to 2,000,000 shares of common stock valued at $71,521 with an exercise price of $0.05 in conjunction with the issuance of a note payable; three-year common stock purchase warrants to acquire up to 4,805,600 shares of common stock with exercise prices ranging from $0.051 to $1.00 in conjunction with the issuance of Series B preferred stock; two-year common stock purchase warrants to acquire up to 3,271,277 shares of common stock with exercise prices ranging from $0.0250 to $0.0516 in conjunction with the issuance of Series C preferred stock; a 2-year common stock purchase warrant to acquire up to 6,200,000 shares of common stock valued at $380,750 with an exercise price of $0.0001; and two-year common stock purchase warrants to acquire up to 642,157 shares of common stock with exercise prices ranging from $0.0368 to $0.0370 in conjunction with the extension of certain notes payable.

The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions:

Nine months ended September 30,

2018

Expected term 2 years - 5 years

Exercise price $0.0001-$0.0516

Expected volatility 158%-193%

Expected dividends None

Risk-free interest rate 1.92% to 2.81%

Forfeitures None

A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below:

Outstanding Warrants

Weighted Average

Exercise Price

Shares Per Share

Outstanding at January 1, 2018 61,807,992 $ 0.31

Granted 18,480,984 $ 0.20

Cancelled (300,000 ) $ 0.81

Exercised - $ -

Outstanding at September 30, 2018 79,988,976 $ 0.28

Exercisable at September 30, 2018 79,988,976 $ 0.28

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1

Related Party Transactions
9 Months Ended

Sep. 30, 2018

Related Party Transactions [Abstract]

Related Party Transactions

Note 7 – Related Party Transactions

One executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from related parties at September 30, 2018 is $270,000.

As of September 30, 2018 and December 31, 2017, the balance of executives’ deferred compensation is $942,650 and $922,425, respectively.

From time-to-time executives of the Company advance monies to the Company to cover costs. During the nine months ended September 30, 2018, executives advanced $65,000 of funds to the Company and received payments of $87,000 resulting in a $0 balance of short-term advances due to executives at September 30, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 8 – Fair Value Measurements

The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

Nine months ended September 30,

2018 2017

Expected term 1 month - 1 year 1 month - 1 year

Exercise price $0.0129-$0.0326 $0.0085-$0.0385

Expected volatility 119%-195% 189%-201%

Expected dividends None None

Risk-free interest rate 1.79% to 2.59% 1.03% to 1.31%

Forfeitures None None

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018:

Derivative

Liability

Balance December 31, 2017 $ 5,939,600

Issuance of convertible debt 1,459,645

Settlements by debt settlement (1,312,833 )

Change in estimated fair value 970,760

Balance September 30, 2018 $ 7,057,172

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018:

Fair Value Measurements Using

Quoted Prices in Significant Other Significant

Active Markets for Observable Unobservable

Identical Assets Inputs Inputs

(Level 1) (Level 2) (Level 3) Total

As of September 30, 2018

Derivative liability $ - $ - $ 7,057,172 $ 7,057,172

Total $ - $ - $ 7,057,172 $ 7,057,172

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1

Commitments and Contingencies
9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

Legal Matters

The Company may become involved in various legal proceedings in the normal course of business.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Events
9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

Note 10 – Subsequent Events

Subsequent to September 30, 2018, an aggregate of 9,236,938 shares of restricted common stock were issued on the conversion of $188,750 of principal and $23,106 of accrued interest pursuant to three Variable Notes.

Subsequent to September 30, 2018, 575,800 shares of restricted common stock were issued on the conversion of $15,000 of principal and $5,153 of accrued interest pursuant to one Fixed Rate Note and issued 3-year warrants for an exercise of up to 575,800 shares of common stock with exercise prices ranging from $0.069 to $1.00.

Subsequent to September 30, 2018, the Company received $85,000 of cash from the issuance of 85 shares of Preferred C Stock and issued two-year warrants for the exercise up to 381,803 shares of common stock with an exercise prices ranging from $0.0380 to $0.0470.

Subsequent to September 30, 2018, 1,000,000 shares of restricted common stock were issued related to services rendered.

Subsequent to September 30, 2018, 2,941,176 shares of restricted common stock were issued on the conversion of 750 shares of Preferred B Stock at a conversion rate of $0.0255 per common share.

As a result of these issuances, the total number of common shares outstanding is 395,129,771. Preferred B shares outstanding is 600 and Preferred C shares outstanding is 1,403.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

Organization and Nature of Business (Policies)
9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.

Going Concern

Going Concern

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

Net Income (Loss) Per Share

Net Income (Loss) per Share

Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

Accounts Receivable

Accounts Receivable

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.

Research and Development

Research and Development

Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements.

In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements.

On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements.

In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2.

In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements.

In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

X

- Definition
Going concern [Policy Text Block]
+ References
No definition available.
+ Details

Name: ENDV_GoingConcernPolicyTextBlock

Namespace Prefix: ENDV_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Recognition (Tables)
9 Months Ended

Sep. 30, 2018

Revenue Recognition [Abstract]

Schedule of Disaggregated by Revenue Source

As of September 30, 2018 and 2017 the sources of revenue were as follows:

Three Months Ended Nine Months Ended

September 30, September 30,

2018 2017 2018 2017

Distributor- Plastic surgeons, net $ - $ - $ 17,045 $ -

Direct sales- Plastic surgeons, gross 21,306 - 24,087 -

Total sources of revenue $ 21,306 $ - $ 41,132 $ -

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property, Plant and Equipment (Tables)
9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Summary of Property, Plant and Equipment

The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017:

September 30, December 31,

2018 2017

Autos $ 64,458 $ 64,458

Medical equipment 13,969 5,000

Other equipment 8,774 8,774

87,201 78,232

Less accumulated depreciation 79,460 77,168

$ 7,741 $ 1,064

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1

Patents (Tables)
9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Patents Less Accumulated Amortization

The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017:

September 30, December 31,

2018 2017

Patents $ 4,500,000 $ 4,500,000

Less accumulated amortization 485,183 -

$ 4,014,817 $ 4,500,000

Schedule of Estimated Future Amortization Expense

The estimated future amortization expense related to patents as of September 30, 2018 is as follows:

Twelve Months Ending September 30, Amount

2019 $ 646,910

2020 646,910

2021 646,910

2022 646,910

2023 646,910

Thereafter 780,267

Total $ 4,014,817

X

- Definition
Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

Notes Payable and Long Term Loan (Tables)
9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Notes Payable

September 30, December 31,

2018 2017

Notes payable at beginning of period $ 7,356,144 $ 3,193,956

Notes payable issued 2,606,870 5,837,070

Settlements on note payable (47,500 ) (95,597 )

Repayments of notes payable in cash (375,500 ) (96,000 )

Less amounts converted to stock (1,127,491 ) (1,483,285 )

Notes payable at end of period 8,412,523 7,356,144

Less debt discount (1,175,627 ) (2,624,984 )

$ 7,236,896 $ 4,731,160

Notes payable issued to related parties $ 270,000 $ 270,000

Notes payable issued to non-related parties $ 6,966,896 $ 4,461,160

Schedule of Maturity Dates of Notes Payable

The maturity dates on the notes payable are as follows:

Twelve months ending, Non-related parties
Related

parties
Total

Past due $ 2,818,653 $ 100,000 $ 2,918,653

September 30, 2019 5,323,870 170,000 5,493,870

Total $ 8,142,523 $ 270,000 $ 8,412,523

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit (Tables)
9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Schedule of Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

Number of Shares Number of Shares Outstanding Par Liquidation

Authorized at September 30, 2018 Value Value

Series AA 1,000,000 5,000 $ 0.0001 $ -

Preferred Series B 50,000 1,350 $ 0.0001 $ 100

Preferred Series C 8,000 1,318 $ 0.0001 $ 1,000

Undesignated 3,942,000 - - -

Schedule of Stock Options Outstanding

The balance of all stock options outstanding as of September 30, 2018 is as follows:

Weighted Weighted Average

Average

Exercise Price
Remaining Contractual
Aggregate

Intrinsic

Options Per Share Term (years) Value

Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96

Granted 1,000,000 $ 0.030 1.86

Cancelled - $ - -

Exercised - $ - -

Outstanding at September 30, 2018 94,203,369 $ 0.029 3.19 $ 2,232,620

Exercisable at September 30, 2018 93,286,702 $ 0.029 3.21 $ 2,210,895

Schedule of Stock Options Valuation of Assumptions

The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions:

Nine months ended September 30,

2018

Expected term 2 years - 5 years

Exercise price $0.0001-$0.0516

Expected volatility 158%-193%

Expected dividends None

Risk-free interest rate 1.92% to 2.81%

Forfeitures None

Schedule of Warrants Outstanding

A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below:

Outstanding Warrants

Weighted Average

Exercise Price

Shares Per Share

Outstanding at January 1, 2018 61,807,992 $ 0.31

Granted 18,480,984 $ 0.20

Cancelled (300,000 ) $ 0.81

Exercised - $ -

Outstanding at September 30, 2018 79,988,976 $ 0.28

Exercisable at September 30, 2018 79,988,976 $ 0.28

X

- Definition
Schedule of preferred stock [Table Text Block]
+ References
No definition available.
+ Details

Name: ENDV_ScheduleOfPreferredStockTableTextBlock

Namespace Prefix: ENDV_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Stock Option Valuation Assumptions

The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

Nine months ended September 30,

2018 2017

Expected term 1 month - 1 year 1 month - 1 year

Exercise price $0.0129-$0.0326 $0.0085-$0.0385

Expected volatility 119%-195% 189%-201%

Expected dividends None None

Risk-free interest rate 1.79% to 2.59% 1.03% to 1.31%

Forfeitures None None

Schedule of Changes in Liabilities with Significant Unobservable Inputs

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018:

Derivative

Liability

Balance December 31, 2017 $ 5,939,600

Issuance of convertible debt 1,459,645

Settlements by debt settlement (1,312,833 )

Change in estimated fair value 970,760

Balance September 30, 2018 $ 7,057,172

Schedule of Balance in Liabilities with Significant Unobservable Inputs

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018:

Fair Value Measurements Using

Quoted Prices in Significant Other Significant

Active Markets for Observable Unobservable

Identical Assets Inputs Inputs

(Level 1) (Level 2) (Level 3) Total

As of September 30, 2018

Derivative liability $ - $ - $ 7,057,172 $ 7,057,172

Total $ - $ - $ 7,057,172 $ 7,057,172

X

- Definition
Schedule of Balance in Liabilities with Significant Unobservable Inputs [Table Text Block]
+ References
No definition available.
+ Details

Name: ENDV_ScheduleOfBalanceInLiabilitiesWithSignificantUnobservableInputsTableTextBlock

Namespace Prefix: ENDV_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(4)
-URI http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

Organization and Nature of Business (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Debt and equity financing $ 3,148,500

Provision for doubtful accounts $ 0 0 $ 0

Research and development expenses $ 5,238 $ 75,346 $ 163,073 $ 115,159

X

- Definition
debt and equity financing.
+ References
No definition available.
+ Details

Name: ENDV_DebtAndEquityFinancing

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Recognition (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Recognized net revenues $ 21,306 $ 41,132

Gross Revenue [Member]

Recognized net revenues $ 21,306 24,087

Product [Member]

Recognized net revenues 17,045

Selling price $ 43,196

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=ENDV_GrossRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Total sources of revenue $ 21,306 $ 41,132

Distributor - Plastic Surgeons Net [Member]

Total sources of revenue 17,045

Direct Sales - Plastic Surgeons Gross [Member]

Total sources of revenue $ 21,306 $ 24,087

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=ENDV_DistributorPlasticSurgeonsNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=ENDV_DirectSalesPlasticSurgeonsGrossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property, Plant and Equipment (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Depreciation expense $ 2,292 $ 11,070

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Property, Plant and Equipment, gross $ 87,201 $ 78,232

Less accumulated depreciation 79,460 77,168

Property, Plant and Equipment, net 7,741 1,064

Autos [Member]

Property, Plant and Equipment, gross 64,458 64,458

Medical Equipment [Member]

Property, Plant and Equipment, gross 13,969 5,000

Other Equipment [Member]

Property, Plant and Equipment, gross $ 8,774 $ 8,774

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENDV_AutosMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENDV_MedicalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENDV_OtherEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1

Patents (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended

Dec. 31, 2017

Sep. 30, 2018

Sep. 30, 2017

Amortization expense $ 485,183 $ 0

Settlement Agreement [Member] | Rio Grande Neurosciences, Inc. [Member]

Acquisition of patents $ 4,500,000

Patents expire period 2024

Patent amortization description Patent portfolio is amortized through 2024

X

- Definition
Patent amortization description.
+ References
No definition available.
+ Details

Name: ENDV_PatentAmortizationDescription

Namespace Prefix: ENDV_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Patents expire period.
+ References
No definition available.
+ Details

Name: ENDV_PatentExpirePeriod

Namespace Prefix: ENDV_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ENDV_SettlementAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ENDV_RioGrandeNeurosciencesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Patents $ 4,500,000 $ 4,500,000

Less accumulated amortization 485,183

Total $ 4,014,817 $ 4,500,000

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

2019 $ 646,910

2020 646,910

2021 646,910

2022 646,910

2023 646,910

Thereafter 780,267

Total $ 4,014,817 $ 4,500,000

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1

Notes Payable and Long Term Loan (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Note payable outstanding $ 6,966,896 $ 4,461,160

Note payable related parties 270,000 $ 270,000

Payments for notes payable 375,500 $ 96,000

Past Maturity [Member]

Note payable related parties 100,000

Convertible Debentures [Member]

Convertible debentures outstanding amount $ 923,870

Debt instrument, interest rates 10.00%

Debt conversion, converted instrument, rates 35.00%

Percentage of issuance note of premium 135.00%

One Convertible Debentures [Member]

Convertible debentures outstanding amount $ 836,000

Fixed Rate Note [Member]

Convertible debentures outstanding amount $ 1,683,000

Fixed Rate Note [Member] | Minimum [Member]

Debt instrument, interest rates 10.00%

Fixed Rate Note [Member] | Maximum [Member]

Debt instrument, interest rates 12.00%

One Fixed Rate Note [Member]

Convertible debentures outstanding amount $ 1,500,000

Convertible Notes With Variable Conversion Rates [Member]

Note payable outstanding 4,212,620

Convertible Notes With Variable Conversion Rates [Member] | Past Maturity [Member]

Note payable outstanding 1,488,750

Other Notes Payable [Member]

Other notes payable outstanding 3,929,903

Other Notes Payable [Member] | Past Maturity [Member]

Other notes payable outstanding $ 1,329,903

X

- Definition
Percentage of issuance note of premium.
+ References
No definition available.
+ Details

Name: ENDV_PercentageOfIssuanceNoteOfPremium

Namespace Prefix: ENDV_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=ENDV_PastMaturityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_ConvertibleDebenturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_OneConvertibleDebenturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_FixedRateNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_OneFixedRateNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_ConvertibleNotesWithVariableConversionRatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Repayments of notes payable in cash $ (375,500) $ (96,000)

Less amounts converted to stock (2,373,739)

Notes Payable [Member]

Notes payable at beginning of period 7,356,144 $ 3,193,956 $ 3,193,956

Notes payable issued 2,606,870 5,837,070

Settlements on note payable (47,500) (95,597)

Repayments of notes payable in cash (375,500) (96,000)

Less amounts converted to stock (1,127,491) (1,483,285)

Notes payable at end of period 8,412,523 7,356,144

Less debt discount (1,175,627) (2,624,984)

Note payable, net 7,236,896 4,731,160

Notes payable issued to related parties 270,000 270,000

Notes payable issued to non-related parties $ 6,966,896 $ 4,461,160

X

- Definition
Notes payable issued to non-related parties.
+ References
No definition available.
+ Details

Name: ENDV_NotesPayableIssuedToNonrelatedParties

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Settlements on note payable.
+ References
No definition available.
+ Details

Name: ENDV_SettlementsOnNotePayable

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesAndLoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_NotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details)

Sep. 30, 2018

USD ($)

Past due $ 2,918,653

June 30, 2019 5,493,870

Total 8,412,523

Non-Related Parties [Member]

Past due 2,818,653

June 30, 2019 5,323,870

Total 8,142,523

Related Parties [Member]

Past due 100,000

June 30, 2019 170,000

Total $ 270,000

X

- Definition
Past due.
+ References
No definition available.
+ Details

Name: ENDV_LongTermDebtPastDue

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ENDV_NonRelatedPartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ENDV_RelatedPartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended

Feb. 22, 2013

Sep. 30, 2018

Feb. 07, 2018

Dec. 31, 2017

Sep. 18, 2018

Dec. 22, 2017

Feb. 07, 2017

Preferred stock, authorized 1,000,000 1,000,000 1,000,000 5,000,000

Common stock, shares authorized 2,500,000,000 2,500,000,000 2,500,000,000

Preferred stock, par value $ 0.0001 $ 0.001 $ 0.001

Preferred stock voting rights Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

Preferred stock, outstanding 5,000 5,000

Preferred stock, shares issued 5,000 5,000

Shares issued for conversion of notes payable and accrued interest $ 2,373,739

Issuance of common stock, value $ 135,000

Issuance of common stock related to services and fees, shares 4,150,000

Issuance of common stock related to services and fees $ 130,235

Shares issued for commitment fees, shares 3,387,534

Shares issued for commitment fees $ 116,531

Notes Payable [Member]

Debt discount 1,175,627 $ 2,624,984

Shares issued for conversion of notes payable and accrued interest $ 1,127,491 1,483,285

Lock-Up Agreement [Member]

Common stock, shares issued 17,003

Issuance of common stock, value $ 1,046

Minimum [Member]

Capital stock authorized 505,000,000

Maximum [Member]

Capital stock authorized 2,505,000,000

Series AA Preferred Stock [Member]

Preferred stock, outstanding 5,000

Series B Convertible Preferred Stock [Member]

Preferred stock, authorized 50,000

Preferred stock, par value $ 100

Preferred stock, outstanding 1,350

Stated value dividend 75.00%

Warrants term 3 years

Share exercise price 1.50

Preferred stock, shares issued 1,350

Common stock, shares issued 1,350

Shares issued for conversion of notes payable and accrued interest, shares

Shares issued for conversion of notes payable and accrued interest

Issuance of common stock, value $ 1

Issuance of common stock related to services and fees, shares

Issuance of common stock related to services and fees

Series C Secured Redeemable Preferred Stock [Member]

Preferred stock, authorized 8,000

Preferred stock dividend per share $ 20.00

Shares issued, price per share $ 1,000

Sale of stock for preferred stock 1,318

Sale of stock, consideration $ 1,317,500

Debt discount $ 152,972 $ 101,808

Series C Secured Redeemable Preferred Stock [Member] | Maximum [Member]

Warrants issued to purchase common stock 5,996,546

Common Stock [Member] | Private Placement [Member]

Common stock, shares issued 1,561,950

Number of warrants issued for cash $ 60,000

Shares issued for conversion of notes payable and accrued interest, shares 58,695,192

Shares issued for conversion of notes payable and accrued interest $ 1,237,256

Preferred Stock Designated [Member]

Preferred stock, authorized 5,000,000

Warrant [Member]

Preferred stock, outstanding 4,805,600

Stated value dividend 0.00%

Warrants term 3 years

Preferred stock, shares issued 4,805,600

Warrants issued to purchase common stock 1,561,950

Warrant [Member] | Minimum [Member]

Warrant exercise price $ 0.0734

Warrant [Member] | Maximum [Member]

Warrant exercise price $ 1.00

Warrant Two [Member]

Warrants term 5 years

Warrants issued to purchase common stock 2,000,000

Warrant exercise price $ 0.05

Warrant value $ 71,521

Warrant Three [Member]

Warrants term 3 years

Warrants issued to purchase common stock 4,805,600

Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Minimum [Member]

Warrant exercise price $ 0.051

Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Maximum [Member]

Warrant exercise price $ 1.00

Warrant Four [Member]

Warrants term 2 years

Warrants issued to purchase common stock 3,271,277

Warrant Four [Member] | Series C Preferred Stock [Member] | Minimum [Member]

Warrant exercise price $ 0.0250

Warrant Four [Member] | Series C Preferred Stock [Member] | Maximum [Member]

Warrant exercise price $ 0.0516

Warrant Five [Member]

Warrants term 2 years

Warrants issued to purchase common stock 6,200,000

Warrant exercise price $ 0.0001

Warrant value $ 380,750

Warrant Six [Member]

Warrants term 2 years

Warrants issued to purchase common stock 642,157

Warrant Six [Member] | Minimum [Member] | Notes Payable [Member]

Warrant exercise price $ 0.0368

Warrant Six [Member] | Maximum [Member] | Notes Payable [Member]

Warrant exercise price $ 0.0370

X

- Definition
Number of warrants issued for cash.
+ References
No definition available.
+ Details

Name: ENDV_NumberOfWarrantsIssuedForCash

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share exercise price, percentage.
+ References
No definition available.
+ Details

Name: ENDV_ShareExercisePrice

Namespace Prefix: ENDV_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued for commitment fees.
+ References
No definition available.
+ Details

Name: ENDV_SharesIssuedForCommitmentFees

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares issued for commitment fees, shares.
+ References
No definition available.
+ Details

Name: ENDV_SharesIssuedForCommitmentFeesShares

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants term.
+ References
No definition available.
+ Details

Name: ENDV_WarrantsTerm

Namespace Prefix: ENDV_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04.16(a))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996
+ Details

Name: us-gaap_CapitalUnitsAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate dividends declared during the period for each share of preferred stock outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsPerShareDeclared

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_PreferredStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_NotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ENDV_LockupAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ENDV_SeriesAAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ENDV_SeriesCSecuredRedeemablePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_PreferredStockDesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_WarrantTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_WarrantThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_WarrantFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_WarrantFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_WarrantSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)

Sep. 30, 2018

Sep. 18, 2018

Dec. 31, 2017

Feb. 22, 2013

Number of Shares Authorized 1,000,000 5,000,000 1,000,000 1,000,000

Number of Shares Outstanding 5,000 5,000

Par Value $ 0.001 $ 0.001 $ 0.0001

Series AA [Member]

Number of Shares Authorized 1,000,000

Number of Shares Outstanding 5,000

Par Value $ 0.0001

Liquidation Value

Preferred Stock B [Member]

Number of Shares Authorized 50,000

Number of Shares Outstanding 1,350

Par Value $ 0.0001

Liquidation Value $ 100

Preferred Stock C [Member]

Number of Shares Authorized 8,000

Number of Shares Outstanding 1,318

Par Value $ 0.0001

Liquidation Value $ 1,000

Undesignated [Member]

Number of Shares Authorized 3,942,000

Number of Shares Outstanding

Par Value

Liquidation Value

X

- Definition
Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_SeriesAAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_PreferredStockBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_PreferredStockCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_UndesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details)
9 Months Ended

Sep. 30, 2018

USD ($)

$ / shares

shares

Equity [Abstract]

Stock Option Outstanding, Beginning Balance | shares 93,203,369

Stock Option Outstanding, Granted | shares 1,000,000

Stock Option Outstanding, Cancelled | shares

Stock Option Outstanding, Exercised | shares

Stock Option Outstanding, Ending Balance | shares 94,203,369

Stock Option Outstanding, Exercisable | shares 93,286,702

Weighted Average Exercise Price, Beginning Balance | $ / shares $ 0.029

Weighted Average Exercise Price, Granted | $ / shares 0.030

Weighted Average Exercise Price, Cancelled | $ / shares

Weighted Average Exercise Price, Exercised | $ / shares

Weighted Average Exercise Price, Ending Balance | $ / shares 0.029

Weighted Average Exercise Price, Exercisable | $ / shares $ 0.029

Weighted Average Remaining Contractual Term (years), Outstanding Beginning 3 years 11 months 15 days

Weighted Average Remaining Contractual Term (years), Granted 1 year 10 months 10 days

Weighted Average Remaining Contractual Term (years), Outstanding Ending 3 years 2 months 8 days

Weighted Average Remaining Contractual Term (years), Exercisable 3 years 2 months 16 days

Aggregated Intrinsic Value, Outstanding | $ $ 2,232,620

Aggregated Intrinsic Value, Exercisable | $ $ 2,210,895

X

- Definition
Weighted average remaining contractual term (years), beginning outstanding.
+ References
No definition available.
+ Details

Name: ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: ENDV_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted

Namespace Prefix: ENDV_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) - Warrant [Member]
9 Months Ended

Sep. 30, 2018

$ / shares

Expected dividends 0.00%

Forfeitures 0.00%

Minimum [Member]

Expected term 2 years

Exercise price $ 0.0001

Expected volatility 158.00%

Risk-free interest rate 1.92%

Maximum [Member]

Expected term 5 years

Exercise price $ 0.0516

Expected volatility 193.00%

Risk-free interest rate 2.81%

X

- Definition
The forfeitures rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitures

Namespace Prefix: ENDV_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]
9 Months Ended

Sep. 30, 2018

$ / shares

shares

Shares Outstanding, Beginning Balance | shares 61,807,992

Shares, Granted | shares 18,480,984

Shares, Cancelled | shares (300,000)

Shares, Exercised | shares

Shares Outstanding, Ending Balance | shares 79,988,976

Shares Exercisable, Ending Balance | shares 79,988,976

Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares $ 0.31

Weighted-Average Exercise Price, Granted | $ / shares 0.20

Weighted average exercise price, Cancelled | $ / shares 0.81

Weighted-Average Exercise Price, Exercised | $ / shares

Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares 0.28

Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares $ 0.28

X

- Definition
Share based compensation arrangement by share based payment award non option equity exercisable.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable

Namespace Prefix: ENDV_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based paymet award non option outstanding weighted average number of share.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageNumberOfShare

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based paymet award non option weighted average exercisable.
+ References
No definition available.
+ Details

Name: ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements that were either cancelled or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1

Related Party Transactions (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Notes payable - related parties $ 270,000 $ 270,000

Repayment of related party debt 87,000 $ 11,500

Executives [Member]

Deferred compensation 942,650 $ 922,425

Related party advances 65,000

Repayment of related party debt 87,000

Short-term advances $ 0

X

- Definition
Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCompensationEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsForAdvanceToAffiliate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ENDV_ExecutivesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) - $ / shares
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Forfeitures 0.00% 0.00%

Measurement Input, Expected Term [Member] | Minimum [Member]

Fair value assumptions, measurement input, term 1 month 1 month

Measurement Input, Expected Term [Member] | Maximum [Member]

Fair value assumptions, measurement input, term 1 year 1 year

Measurement Input, Exercise Price [Member] | Minimum [Member]

Fair value assumptions, measurement input, exercise price $ 0.0129 $ 0.0085

Measurement Input, Exercise Price [Member] | Maximum [Member]

Fair value assumptions, measurement input, exercise price $ 0.0326 $ 0.0385

Measurement Input, Price Volatility [Member] | Minimum [Member]

Fair value assumptions, measurement input, percentage 119.00% 189.00%

Measurement Input, Price Volatility [Member] | Maximum [Member]

Fair value assumptions, measurement input, percentage 195.00% 201.00%

Measurement Input, Expected Dividend Rate [Member]

Fair value assumptions, measurement input, percentage 0.00% 0.00%

Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]

Fair value assumptions, measurement input, percentage 1.79% 1.03%

Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]

Fair value assumptions, measurement input, percentage 2.59% 1.31%

X

- Definition
Fair value assumptions forfeiture rate.
+ References
No definition available.
+ Details

Name: ENDV_FairValueAssumptionsForfeitureRate

Namespace Prefix: ENDV_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value assumptions, measurement input, exercise price.
+ References
No definition available.
+ Details

Name: ENDV_FairValueAssumptionsMeasurementInputExercisePrice

Namespace Prefix: ENDV_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value assumptions, measurement input, percentage.
+ References
No definition available.
+ Details

Name: ENDV_FairValueAssumptionsMeasurementInputPercentage

Namespace Prefix: ENDV_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value assumptions, measurement input, term.
+ References
No definition available.
+ Details

Name: ENDV_FairValueAssumptionsMeasurementInputTerm

Namespace Prefix: ENDV_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details)
9 Months Ended

Sep. 30, 2018

USD ($)

Derivative Liability, ending $ 7,057,172

Significant Unobservable Inputs (Level 3) [Member]

Derivative Liability, beginning 5,939,600

Issuance of convertible debt 1,459,645

Settlements by debt settlement (1,312,833)

Change in estimated fair value 970,760

Derivative Liability, ending $ 7,057,172

X

- Definition
Change in estimated fair value.
+ References
No definition available.
+ Details

Name: ENDV_ChangeInEstimatedFairValue

Namespace Prefix: ENDV_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Gross amount of debt extinguished.
+ References
No definition available.
+ Details

Name: us-gaap_ExtinguishmentOfDebtAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=ENDV_SignificantUnobservableInputsLevelThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details)

Sep. 30, 2018

USD ($)

Derivative liability $ 7,057,172

Total 7,057,172

Fair Value, Inputs, Level 1 [Member]

Derivative liability

Total

Fair Value, Inputs, Level 2 [Member]

Derivative liability

Total

Fair Value, Inputs, Level 3 [Member]

Derivative liability 7,057,172

Total $ 7,057,172

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FinancialLiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Events (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Issuance of restricted common stock, value $ 2,373,739

Number of shares issued, value $ 135,000

Number of shares issued for services 4,150,000

Two Year Warrant One [Member]

Warrants term 2 years

Warrant to purchase common stock 381,803

Common Stock [Member]

Issuance of restricted common stock, shares 58,695,192

Issuance of restricted common stock, value $ 5,870

Number of shares issued, value

Number of shares issued

Number of shares issued for services 4,150,000

Number of shares outstanding 381,375,857 316,951,712

Preferred B Stock [Member]

Number of shares outstanding 600

Subsequent to September 30, 2018 [Member] | Common Stock [Member]

Number of shares outstanding 395,129,771

Subsequent to September 30, 2018 [Member] | Preferred C Stock [Member]

Number of shares outstanding 1,403

Preferred C Stock [Member]

Number of shares issued, value $ 85,000

Number of shares issued 85

Minimum [Member] | Two Year Warrant One [Member]

Warrant exercise price $ 0.0380

Maximum [Member] | Two Year Warrant One [Member]

Warrant exercise price $ 0.0470

Restricted Common Stock [Member]

Issuance of restricted common stock, shares 2,941,176

Number of shares issued for services 1,000,000

Conversion of shares converted 750

Conversion rate price per share $ 0.0255

Restricted Common Stock [Member] | Three Variable Note [Member]

Issuance of restricted common stock, shares 9,236,938

Issuance of restricted common stock, value $ 188,750

Accrued interest $ 23,106

Restricted Common Stock [Member] | One Variable Note [Member]

Issuance of restricted common stock, shares 575,800

Issuance of restricted common stock, value $ 15,000

Accrued interest $ 5,153

Warrants term 3 years

Restricted Common Stock [Member] | One Variable Note [Member] | Minimum [Member]

Warrant exercise price $ 0.069

Restricted Common Stock [Member] | One Variable Note [Member] | Maximum [Member]

Warrant exercise price $ 1.00

X

- Definition
Warrants term.
+ References
No definition available.
+ Details

Name: ENDV_WarrantsTerm

Namespace Prefix: ENDV_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Increase for accrued, but unpaid interest on the debt instrument for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentIncreaseAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_TwoYearWarrantOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_PreferredBStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=ENDV_SubsequentToSeptemberThirtyTwoThousandEighteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ENDV_PreferredCStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ENDV_PreferredCStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ENDV_RestrictedCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_ThreeVariableNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ENDV_OneVariableNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 150 241 1 false 62 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://endonovo.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://endonovo.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://endonovo.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://endonovo.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://endonovo.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) Sheet http://endonovo.com/role/StatementOfShareholdersDeficit Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Business Sheet http://endonovo.com/role/OrganizationAndNatureOfBusiness Organization and Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Revenue Recognition Sheet http://endonovo.com/role/RevenueRecognition Revenue Recognition Notes 8 false false R9.htm 00000009 - Disclosure - Property, Plant and Equipment Sheet http://endonovo.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Patents Sheet http://endonovo.com/role/Patents Patents Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable and Long Term Loan Notes http://endonovo.com/role/NotesPayableAndLongTermLoan Notes Payable and Long Term Loan Notes 11 false false R12.htm 00000012 - Disclosure - Shareholders' Deficit Sheet http://endonovo.com/role/ShareholdersDeficit Shareholders' Deficit Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://endonovo.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Fair Value Measurements Sheet http://endonovo.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://endonovo.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://endonovo.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Organization and Nature of Business (Policies) Sheet http://endonovo.com/role/OrganizationAndNatureOfBusinessPolicies Organization and Nature of Business (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - Revenue Recognition (Tables) Sheet http://endonovo.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://endonovo.com/role/RevenueRecognition 18 false false R19.htm 00000019 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://endonovo.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://endonovo.com/role/PropertyPlantAndEquipment 19 false false R20.htm 00000020 - Disclosure - Patents (Tables) Sheet http://endonovo.com/role/PatentsTables Patents (Tables) Tables http://endonovo.com/role/Patents 20 false false R21.htm 00000021 - Disclosure - Notes Payable and Long Term Loan (Tables) Notes http://endonovo.com/role/NotesPayableAndLongTermLoanTables Notes Payable and Long Term Loan (Tables) Tables http://endonovo.com/role/NotesPayableAndLongTermLoan 21 false false R22.htm 00000022 - Disclosure - Shareholders' Deficit (Tables) Sheet http://endonovo.com/role/ShareholdersDeficitTables Shareholders' Deficit (Tables) Tables http://endonovo.com/role/ShareholdersDeficit 22 false false R23.htm 00000023 - Disclosure - Fair Value Measurements (Tables) Sheet http://endonovo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://endonovo.com/role/FairValueMeasurements 23 false false R24.htm 00000024 - Disclosure - Organization and Nature of Business (Details Narrative) Sheet http://endonovo.com/role/OrganizationAndNatureOfBusinessDetailsNarrative Organization and Nature of Business (Details Narrative) Details http://endonovo.com/role/OrganizationAndNatureOfBusinessPolicies 24 false false R25.htm 00000025 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://endonovo.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://endonovo.com/role/RevenueRecognitionTables 25 false false R26.htm 00000026 - Disclosure - Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) Sheet http://endonovo.com/role/RevenueRecognition-ScheduleOfDisaggregatedByRevenueSourceDetails Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) Details 26 false false R27.htm 00000027 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://endonovo.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://endonovo.com/role/PropertyPlantAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) Sheet http://endonovo.com/role/PropertyPlantAndEquipment-SummaryOfPropertyPlantAndEquipmentDetails Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) Details 28 false false R29.htm 00000029 - Disclosure - Patents (Details Narrative) Sheet http://endonovo.com/role/PatentsDetailsNarrative Patents (Details Narrative) Details http://endonovo.com/role/PatentsTables 29 false false R30.htm 00000030 - Disclosure - Patents - Schedule of Patents Less Accumulated Amortization (Details) Sheet http://endonovo.com/role/Patents-ScheduleOfPatentsLessAccumulatedAmortizationDetails Patents - Schedule of Patents Less Accumulated Amortization (Details) Details 30 false false R31.htm 00000031 - Disclosure - Patents - Schedule of Estimated Future Amortization Expense (Details) Sheet http://endonovo.com/role/Patents-ScheduleOfEstimatedFutureAmortizationExpenseDetails Patents - Schedule of Estimated Future Amortization Expense (Details) Details 31 false false R32.htm 00000032 - Disclosure - Notes Payable and Long Term Loan (Details Narrative) Notes http://endonovo.com/role/NotesPayableAndLongTermLoanDetailsNarrative Notes Payable and Long Term Loan (Details Narrative) Details http://endonovo.com/role/NotesPayableAndLongTermLoanTables 32 false false R33.htm 00000033 - Disclosure - Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) Notes http://endonovo.com/role/NotesPayableAndLongTermLoan-ScheduleOfNotesPayableDetails Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) Details 33 false false R34.htm 00000034 - Disclosure - Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details) Notes http://endonovo.com/role/NotesPayableAndLongTermLoan-ScheduleOfMaturityDatesOfNotesPayableDetails Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details) Details 34 false false R35.htm 00000035 - Disclosure - Shareholders' Deficit (Details Narrative) Sheet http://endonovo.com/role/ShareholdersDeficitDetailsNarrative Shareholders' Deficit (Details Narrative) Details http://endonovo.com/role/ShareholdersDeficitTables 35 false false R36.htm 00000036 - Disclosure - Shareholders' Deficit - Schedule of Preferred Stock (Details) Sheet http://endonovo.com/role/ShareholdersDeficit-ScheduleOfPreferredStockDetails Shareholders' Deficit - Schedule of Preferred Stock (Details) Details 36 false false R37.htm 00000037 - Disclosure - Shareholders' Deficit - Schedule of Stock Options Outstanding (Details) Sheet http://endonovo.com/role/ShareholdersDeficit-ScheduleOfStockOptionsOutstandingDetails Shareholders' Deficit - Schedule of Stock Options Outstanding (Details) Details 37 false false R38.htm 00000038 - Disclosure - Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) Sheet http://endonovo.com/role/ShareholdersDeficit-ScheduleOfStockOptionsValuationOfAssumptionsDetails Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) Details 38 false false R39.htm 00000039 - Disclosure - Shareholders' Deficit - Schedule of Warrants Outstanding (Details) Sheet http://endonovo.com/role/ShareholdersDeficit-ScheduleOfWarrantsOutstandingDetails Shareholders' Deficit - Schedule of Warrants Outstanding (Details) Details 39 false false R40.htm 00000040 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://endonovo.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://endonovo.com/role/RelatedPartyTransactions 40 false false R41.htm 00000041 - Disclosure - Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) Sheet http://endonovo.com/role/FairValueMeasurements-ScheduleOfStockOptionValuationAssumptionsDetails Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) Details 41 false false R42.htm 00000042 - Disclosure - Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details) Sheet http://endonovo.com/role/FairValueMeasurements-ScheduleOfChangesInLiabilitiesWithSignificantUnobservableInputsDetails Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details) Details 42 false false R43.htm 00000043 - Disclosure - Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details) Sheet http://endonovo.com/role/FairValueMeasurements-ScheduleOfBalanceInLiabilitiesWithSignificantUnobservableInputsDetails Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details) Details 43 false false R44.htm 00000044 - Disclosure - Subsequent Events (Details Narrative) Sheet http://endonovo.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://endonovo.com/role/SubsequentEvents 44 false false All Reports Book All Reports endv-20180930.xml endv-20180930.xsd endv-20180930_cal.xml endv-20180930_def.xml endv-20180930_lab.xml endv-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 61 0001493152-18-015639-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-015639-xbrl.zip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end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 08, 2018
Document And Entity Information
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		395,129,771
Trading Symbol	ENDV
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 665,244	$ 90,173
Accounts receivable	2,650
Prepaid expenses and other current assets	21,000	21,000
Total current assets	688,894	111,173
Property Plant and Equipment, net	7,741	1,064
Patents, net	4,014,817	4,500,000
Total assets	4,711,452	4,612,237
Current Liabilities
Accounts payable and accrued expenses	3,179,602	2,714,041
Short term advances		20,323
Notes payable, net of discounts of $1,175,627 as of Septebmer 30, 2018 and $2,624,984 as of December 31, 2017	6,966,896	4,461,160
Notes payable - related parties	270,000	270,000
Derivative liability	7,057,172	5,939,600
Current portion of long term loan		4,221
Total current liabilities	17,473,670	13,409,345
Series C preferred stock liability, net of discounts of $152,972 at September 30, 2018 and $101,808 as of December 31, 2017	1,164,528	598,192
Acquisition payable	155,000	155,000
Total liabilities	18,793,198	14,162,537
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at September 30, 2018 and December 31, 2017	5	5
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at September 30, 2018 and December 31, 2017	1
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 381,375,857 and 316,951,712 shares issued and outstanding as of Septermber 30, 2018 and December 31, 2017	38,136	31,692
Additional paid-in capital	22,884,078	19,604,016
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(37,002,396)	(29,184,443)
Total shareholders' deficit	(14,081,746)	(9,550,300)
Total liabilities and shareholders' deficit	$ 4,711,452	$ 4,612,237

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Discounts on current notes payable	$ 1,175,627	$ 2,624,984
Super AA super voting preferred stock, par value	$ 0.001	$ 0.001
Super AA super voting preferred stock, shares authorized	1,000,000	1,000,000
Super AA super voting preferred stock, shares issued	5,000	5,000
Super AA super voting preferred stock, shares outstanding	5,000	5,000
Series B convertible preferred stock, par value	$ 0.0001	$ 0.0001
Series B convertible preferred stock, shares authorized	50,000	50,000
Series B convertible preferred stock, shares issued	1,350	0
Series B convertible preferred stock, shares outstanding	1,350	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	381,375,857	316,951,712
Common stock, shares outstanding	381,375,857	316,951,712
Series C Preferred Stock [Member]
Series C preferred stock liability, net of discounts	$ 152,972	$ 101,808

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 21,306		$ 41,132
Cost of revenue	4,312		4,862
Gross profit	16,994		36,270
Operating expenses	1,052,210	1,035,628	3,163,485	3,770,929
Loss from operations	(1,035,216)	(1,035,628)	(3,127,215)	(3,770,929)
Other income (expense)
Change in fair value of derivative liability	(3,431,939)	(4,544,656)	(970,760)	(6,945,434)
Gain (loss) on settlement of debt	49,806	(58,197)	308,151	2,175,459
Settlement expenses		(80,000)		(80,000)
Interest expense, net	(1,530,847)	(953,623)	(4,028,129)	(3,958,187)
Other income (expense)	(4,912,980)	(5,636,476)	(4,690,738)	(8,808,162)
Loss before income taxes	(5,948,196)	(6,672,104)	(7,817,953)	(12,579,091)
Provision for income taxes
Net loss	$ (5,948,196)	$ (6,672,104)	$ (7,817,953)	$ (12,579,091)
Basic and diluted loss per share	$ (0.02)	$ (0.03)	$ (0.02)	$ (0.06)
Weighted average common shares outstanding:
Basic and diluted	369,234,308	263,535,090	348,379,894	220,353,026

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net loss	$ (7,817,953)	$ (12,579,091)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	487,474	11,070
Fair value of shares issued for services	130,235	1,410,071
Gain on extinguishment of debt	(308,151)	(2,175,459)
Amortization of note discount and original issue discount	2,647,939	1,467,888
Amortization of discount on Series C Preferred stock liability	61,912
Non-cash interest expense	623,917	2,465,912
Non-cash value of warrant and stock options issued for services	382,473
Change in fair value of derivative liability	970,760	6,945,434
Changes in assets and liabilities:
Accounts receivable	(2,650)
Prepaid expenses and other current assets		156,321
Accounts payable and accrued expenses	661,305	108,658
Net cash used in operating activities	(2,162,739)	(2,189,196)
Investing activities:
Acquisition of property and equipment	(8,969)
Net cash used in investing activities	(8,969)
Financing activities:
Proceeds from the issuance of notes payable	2,336,000	1,562,000
Proceeds from related party short-term advances	65,000	12,650
Repayments on related parties short term advances	(87,000)	(11,500)
Proceeds from issuance of preferred stock	135,000	5
Proceeds from issuance of common stock and units	60,000	740,250
Payment against long term loan	(4,221)	(9,263)
Payment against notes payable	(375,500)	(96,000)
Proceeds from issuance of redeemable shares	617,500
Net cash provided by financing activities	2,746,779	2,198,142
Net increase in cash	575,071	8,946
Cash, beginning of year	90,173	55,533
Cash, end of period	665,244	64,479
Supplemental disclosure of cash flow information:
Cash paid for interest	122,445	27,022
Cash paid for Preferred C dividends	37,950
Cash paid for income taxes
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	1,237,256	1,108,321
Reduction in note payable and accrued interest as result of settlement	82,000
Common stock issued on settlement of debt		289,675
Notes payable and accrued interest exchanged for common stock units		66,367
Value of stock options granted in satisfaction of deferred compensation		$ 1,467,311

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Series AA Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017	$ 5		$ 31,692	$ 19,604,016	$ (1,570)	$ (29,184,443)	$ (9,550,300)
Balance, shares at Dec. 31, 2017	5,000		316,951,712
Private placement units issued for cash			$ 156	59,844			60,000
Private placement units issued for cash, shares			1,561,950
Preferred stock issued for cash		$ 1		134,999			135,000
Preferred stock issued for cash, shares		1,350
Share issued for services			$ 416	129,819			$ 130,235
Share issued for services, shares			4,150,000				4,150,000
Shares issued with lock-up agreements			$ 2	1,044			$ 1,046
Shares issued with lock-up agreements, shares			17,003
Shares issued for conversion of notes payable and accrued interest			$ 5,870	2,367,869			2,373,739
Shares issued for conversion of notes payable and accrued interest, shares			58,695,192
Valuation of warrants issued with Preferred Series C				113,076			113,076
Valuation of warrant and stock options issued for services				382,473			382,473
Valuation of warrants issued with note payable				71,521			71,521
Valuation of warrants issued for extension of notes				19,417			19,417
Net loss						(7,817,953)	(7,817,953)
Balance at Sep. 30, 2018	$ 5	$ 1	$ 38,136	$ 22,884,078	$ (1,570)	$ (37,002,396)	$ (14,081,746)
Balance, shares at Sep. 30, 2018	5,000	1,350	381,375,857

Organization and Nature of Business (Policies)	9 Months Ended
Organization and Nature of Business (Policies)	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development. Research and development costs amounted to $5,238 and $75,346 for the three months ended September 30, 2018 and 2017 and $163,073 and $115,159 for the nine months ended September 30, 2018 and 2017, respectively, and are included in operating expenses in the condensed consolidated statements of operations.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows and ASU 2016-18, Restricted Cash (“ASU 2016-18”), which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-15 and ASU 2016-18 are effective for us beginning January 1, 2017 and was applied by us using a retrospective transition method. Adoption of these standards did not have an impact on our Consolidated Financial Statements. In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which requires a company to recognize the tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for us beginning January 1, 2017 and was applied by us using a modified retrospective method. Adoption of this standard did not have an impact on our Consolidated Financial Statements. On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation (“ASU 2016-09”) which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. Adoption of ASU 2016-09 did not have a significant impact on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements. In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. The Company adopted ASU 2014-09 effective January 1, 2018 using the modified retrospective method. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. See Note 2. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Revenue Recognition (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Recognized net revenues	$ 21,306		$ 41,132
Gross Revenue [Member]
Recognized net revenues	$ 21,306		24,087
Product [Member]
Recognized net revenues			17,045
Selling price			$ 43,196

Property, Plant and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,292	$ 11,070

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, gross	$ 87,201	$ 78,232
Less accumulated depreciation	79,460	77,168
Property, Plant and Equipment, net	7,741	1,064
Autos [Member]
Property, Plant and Equipment, gross	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment, gross	13,969	5,000
Other Equipment [Member]
Property, Plant and Equipment, gross	$ 8,774	$ 8,774

Patents (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
Patents (Details Narrative) - USD ($)	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Amortization expense		$ 485,183	$ 0
Settlement Agreement [Member] \| Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expire period	2024
Patent amortization description	Patent portfolio is amortized through 2024

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	485,183
Total	$ 4,014,817	$ 4,500,000

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 646,910
2020	646,910
2021	646,910
2022	646,910
2023	646,910
Thereafter	780,267
Total	$ 4,014,817	$ 4,500,000

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details)	Sep. 30, 2018 USD ($)
Past due	$ 2,918,653
June 30, 2019	5,493,870
Total	8,412,523
Non-Related Parties [Member]
Past due	2,818,653
June 30, 2019	5,323,870
Total	8,142,523
Related Parties [Member]
Past due	100,000
June 30, 2019	170,000
Total	$ 270,000

Shareholders' Deficit (Details Narrative) - USD ($)		9 Months Ended	12 Months Ended
Shareholders' Deficit (Details Narrative) - USD ($)	Feb. 22, 2013	Sep. 30, 2018	Feb. 07, 2018	Dec. 31, 2017	Sep. 18, 2018	Dec. 22, 2017	Feb. 07, 2017
Preferred stock, authorized	1,000,000	1,000,000		1,000,000	5,000,000
Common stock, shares authorized		2,500,000,000		2,500,000,000	2,500,000,000
Preferred stock, par value	$ 0.0001	$ 0.001		$ 0.001
Preferred stock voting rights	Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, outstanding		5,000		5,000
Preferred stock, shares issued		5,000		5,000
Shares issued for conversion of notes payable and accrued interest		$ 2,373,739
Issuance of common stock, value		$ 135,000
Issuance of common stock related to services and fees, shares		4,150,000
Issuance of common stock related to services and fees		$ 130,235
Shares issued for commitment fees, shares		3,387,534
Shares issued for commitment fees		$ 116,531
Notes Payable [Member]
Debt discount		1,175,627		$ 2,624,984
Shares issued for conversion of notes payable and accrued interest		$ 1,127,491		1,483,285
Lock-Up Agreement [Member]
Common stock, shares issued		17,003
Issuance of common stock, value		$ 1,046
Minimum [Member]
Capital stock authorized					505,000,000
Maximum [Member]
Capital stock authorized					2,505,000,000
Series AA Preferred Stock [Member]
Preferred stock, outstanding		5,000
Series B Convertible Preferred Stock [Member]
Preferred stock, authorized							50,000
Preferred stock, par value							$ 100
Preferred stock, outstanding		1,350
Stated value dividend			75.00%
Warrants term			3 years
Share exercise price			1.50
Preferred stock, shares issued		1,350
Common stock, shares issued		1,350
Shares issued for conversion of notes payable and accrued interest, shares
Shares issued for conversion of notes payable and accrued interest
Issuance of common stock, value		$ 1
Issuance of common stock related to services and fees, shares
Issuance of common stock related to services and fees
Series C Secured Redeemable Preferred Stock [Member]
Preferred stock, authorized						8,000
Preferred stock dividend per share		$ 20.00
Shares issued, price per share						$ 1,000
Sale of stock for preferred stock		1,318
Sale of stock, consideration		$ 1,317,500
Debt discount		$ 152,972		$ 101,808
Series C Secured Redeemable Preferred Stock [Member] \| Maximum [Member]
Warrants issued to purchase common stock		5,996,546
Common Stock [Member] \| Private Placement [Member]
Common stock, shares issued		1,561,950
Number of warrants issued for cash		$ 60,000
Shares issued for conversion of notes payable and accrued interest, shares		58,695,192
Shares issued for conversion of notes payable and accrued interest		$ 1,237,256
Preferred Stock Designated [Member]
Preferred stock, authorized		5,000,000
Warrant [Member]
Preferred stock, outstanding		4,805,600
Stated value dividend		0.00%
Warrants term		3 years
Preferred stock, shares issued		4,805,600
Warrants issued to purchase common stock		1,561,950
Warrant [Member] \| Minimum [Member]
Warrant exercise price		$ 0.0734
Warrant [Member] \| Maximum [Member]
Warrant exercise price		$ 1.00
Warrant Two [Member]
Warrants term		5 years
Warrants issued to purchase common stock		2,000,000
Warrant exercise price		$ 0.05
Warrant value		$ 71,521
Warrant Three [Member]
Warrants term		3 years
Warrants issued to purchase common stock		4,805,600
Warrant Three [Member] \| Series B Convertible Preferred Stock [Member] \| Minimum [Member]
Warrant exercise price		$ 0.051
Warrant Three [Member] \| Series B Convertible Preferred Stock [Member] \| Maximum [Member]
Warrant exercise price		$ 1.00
Warrant Four [Member]
Warrants term		2 years
Warrants issued to purchase common stock		3,271,277
Warrant Four [Member] \| Series C Preferred Stock [Member] \| Minimum [Member]
Warrant exercise price		$ 0.0250
Warrant Four [Member] \| Series C Preferred Stock [Member] \| Maximum [Member]
Warrant exercise price		$ 0.0516
Warrant Five [Member]
Warrants term		2 years
Warrants issued to purchase common stock		6,200,000
Warrant exercise price		$ 0.0001
Warrant value		$ 380,750
Warrant Six [Member]
Warrants term		2 years
Warrants issued to purchase common stock		642,157
Warrant Six [Member] \| Minimum [Member] \| Notes Payable [Member]
Warrant exercise price		$ 0.0368
Warrant Six [Member] \| Maximum [Member] \| Notes Payable [Member]
Warrant exercise price		$ 0.0370

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)	Sep. 30, 2018	Sep. 18, 2018	Dec. 31, 2017	Feb. 22, 2013
Number of Shares Authorized	1,000,000	5,000,000	1,000,000	1,000,000
Number of Shares Outstanding	5,000		5,000
Par Value	$ 0.001		$ 0.001	$ 0.0001
Series AA [Member]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	5,000
Par Value	$ 0.0001
Liquidation Value
Preferred Stock B [Member]
Number of Shares Authorized	50,000
Number of Shares Outstanding	1,350
Par Value	$ 0.0001
Liquidation Value	$ 100
Preferred Stock C [Member]
Number of Shares Authorized	8,000
Number of Shares Outstanding	1,318
Par Value	$ 0.0001
Liquidation Value	$ 1,000
Undesignated [Member]
Number of Shares Authorized	3,942,000
Number of Shares Outstanding
Par Value
Liquidation Value

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares
Equity [Abstract]
Stock Option Outstanding, Beginning Balance \| shares	93,203,369
Stock Option Outstanding, Granted \| shares	1,000,000
Stock Option Outstanding, Cancelled \| shares
Stock Option Outstanding, Exercised \| shares
Stock Option Outstanding, Ending Balance \| shares	94,203,369
Stock Option Outstanding, Exercisable \| shares	93,286,702
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 0.029
Weighted Average Exercise Price, Granted \| $ / shares	0.030
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Ending Balance \| $ / shares	0.029
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 0.029
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 years 11 months 15 days
Weighted Average Remaining Contractual Term (years), Granted	1 year 10 months 10 days
Weighted Average Remaining Contractual Term (years), Outstanding Ending	3 years 2 months 8 days
Weighted Average Remaining Contractual Term (years), Exercisable	3 years 2 months 16 days
Aggregated Intrinsic Value, Outstanding \| $	$ 2,232,620
Aggregated Intrinsic Value, Exercisable \| $	$ 2,210,895

Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Expected dividends	0.00%
Forfeitures	0.00%
Minimum [Member]
Expected term	2 years
Exercise price	$ 0.0001
Expected volatility	158.00%
Risk-free interest rate	1.92%
Maximum [Member]
Expected term	5 years
Exercise price	$ 0.0516
Expected volatility	193.00%
Risk-free interest rate	2.81%

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Shares Outstanding, Beginning Balance \| shares	61,807,992
Shares, Granted \| shares	18,480,984
Shares, Cancelled \| shares	(300,000)
Shares, Exercised \| shares
Shares Outstanding, Ending Balance \| shares	79,988,976
Shares Exercisable, Ending Balance \| shares	79,988,976
Weighted-Average Exercise Price, Outstanding Beginning Balance \| $ / shares	$ 0.31
Weighted-Average Exercise Price, Granted \| $ / shares	0.20
Weighted average exercise price, Cancelled \| $ / shares	0.81
Weighted-Average Exercise Price, Exercised \| $ / shares
Weighted-Average Exercise Price, Outstanding Ending Balance \| $ / shares	0.28
Weighted-Average Exercise Price, Exercisable Ending Balance \| $ / shares	$ 0.28

Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details)	9 Months Ended
	Sep. 30, 2018 USD ($)
Derivative Liability, ending	$ 7,057,172
Significant Unobservable Inputs (Level 3) [Member]
Derivative Liability, beginning	5,939,600
Issuance of convertible debt	1,459,645
Settlements by debt settlement	(1,312,833)
Change in estimated fair value	970,760
Derivative Liability, ending	$ 7,057,172

Subsequent Events (Details Narrative) - USD ($)	9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Issuance of restricted common stock, value	$ 2,373,739
Number of shares issued, value	$ 135,000
Number of shares issued for services	4,150,000
Two Year Warrant One [Member]
Warrants term	2 years
Warrant to purchase common stock	381,803
Common Stock [Member]
Issuance of restricted common stock, shares	58,695,192
Issuance of restricted common stock, value	$ 5,870
Number of shares issued, value
Number of shares issued
Number of shares issued for services	4,150,000
Number of shares outstanding	381,375,857	316,951,712
Preferred B Stock [Member]
Number of shares outstanding	600
Subsequent to September 30, 2018 [Member] \| Common Stock [Member]
Number of shares outstanding	395,129,771
Subsequent to September 30, 2018 [Member] \| Preferred C Stock [Member]
Number of shares outstanding	1,403
Preferred C Stock [Member]
Number of shares issued, value	$ 85,000
Number of shares issued	85
Minimum [Member] \| Two Year Warrant One [Member]
Warrant exercise price	$ 0.0380
Maximum [Member] \| Two Year Warrant One [Member]
Warrant exercise price	$ 0.0470
Restricted Common Stock [Member]
Issuance of restricted common stock, shares	2,941,176
Number of shares issued for services	1,000,000
Conversion of shares converted	750
Conversion rate price per share	$ 0.0255
Restricted Common Stock [Member] \| Three Variable Note [Member]
Issuance of restricted common stock, shares	9,236,938
Issuance of restricted common stock, value	$ 188,750
Accrued interest	$ 23,106
Restricted Common Stock [Member] \| One Variable Note [Member]
Issuance of restricted common stock, shares	575,800
Issuance of restricted common stock, value	$ 15,000
Accrued interest	$ 5,153
Warrants term	3 years
Restricted Common Stock [Member] \| One Variable Note [Member] \| Minimum [Member]
Warrant exercise price	$ 0.069
Restricted Common Stock [Member] \| One Variable Note [Member] \| Maximum [Member]
Warrant exercise price	$ 1.00